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Abstract
Nonlinear delay-differential equations represent infinite-dimensional systems for which
characterising the behaviour of solutions can be technically challenging. Their ap-
pearance in many applied fields, such as population biology, is in great part due to
their ability to model dynamics with non-instantaneous effects. These phenomena
often exhibit behaviour which does not occur in the associated non-delayed counter-
part. In particular, it is known that delays can trigger the occurrence of oscillatory
behaviour and can, in several cases, bring evidence for mechanisms underlying os-
cillations in biological systems. Oscillatory dynamics play an important role in the
accurate regulation of hormones. Such rhythms in the ultradian regime have been
observed in multiple physiological areas such as the HPA-axis, phases of sleep, and
the glucose regulatory system.
In this contribution, the effect of diabetic deficiencies on the production of an
oscillatory ultradian regime is studied using a deterministic nonlinear model which
incorporates two physiological delays. It is shown that insulin resistance impairs
the production of oscillations by dampening the ultradian cycles. Four strategies for
restoring healthy regulation are explored. The model is thus shown to be suitable for
representing the effect of diabetes on the oscillatory regulation and for investigating
pathways to reinstating a physiological healthy regime.
Furthermore, a simplified nonlinear polynomial model of the ultradian oscilla-
tions in glucose-insulin regulation, at the organ and tissue level, is studied. Par-
ticular attention is given to its periodic solutions, arising from a Hopf bifurcation
which is induced by delays in pancreatic insulin release, hepatic glycogenesis and a
glucose infusion. The model also includes terms accounting for insulin independent
and dependent glucose utilisation as well as insulin clearance.
The effect of each of these functions on the amplitude and period of the oscil-
lations is exhibited by performing a Poincare´ perturbative analysis of its periodic
solutions.
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Chapter 1
Introduction
1.1 Mathematical biology
Mathematical biology is a research area that combines significant mathematical
problems with intriguing biology (Hoppensteadt 1995). While there is no exact
formula to detail how to make a successful collaboration between a biologist and a
mathematician, generally one could assume the former would describe a set of exper-
iments or propose a biological question, while the latter would formulate a model
replicating the experiment/biological system and simulate to ensure physiological
accuracy (Friedman 2010). The model may then to be able to identify important
mechanisms within the biological system or suggest new biological testable hypothe-
ses (Friedman 2010). However, interdisciplinary research has its challenges and
mathematical biology is no exception. It could even be asserted that mathematical
biology faces additional challenges when compared to other areas of interdisciplinary
research (Reed 2004). For example, while there exists fundamental central principles
in mathematical physics (i.e. Newton’s laws of motion), no such fundamental princi-
ples exist for mathematical biology, with each problem containing assumptions that
are context specific (Reed 2004). It can therefore be argued that pure mathemati-
cians wanting to work on biological problems must have motivation for the study of
biology, and not just for developing mathematical principles (Reed 2004).
There are many instances of successful collaborations in the field of mathematical
biology (Hoppensteadt 1995, Friedman 2010). Indeed, mathematics has affected
1
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many areas of biology and is a growing field (Hoppensteadt 1995, Friedman 2010).
One such area where mathematics has brought a significant contribution is the study
of diabetes (Ajmera et al. 2013).
1.2 Diabetes
Diabetes mellitus is a chronic metabolic disorder which impairs the regulation of
the glucose and insulin blood levels (Centers for Disease Control and Prevention
et al. 2011), and it can be thought of as a failure of homoeostasis (Nguyen 2018).
Homoeostasis refers to the body’s ability to maintain certain variables, called reg-
ulated variables (Fossion et al. 2018), at, or close to, a healthy value, or steady
state (Cannon 1932, Thomas, Thieffry & Kaufman 1995). The steady state may
be stable, leading to constant levels over time, or unstable, leading to sustained
oscillations (Thomas et al. 1995). The maintenance of these regulated variables is
achieved through the physiological responses triggered by effector variables (Fossion
et al. 2018), and is highly influenced by negative feedback loops which occur within
the body (Cannon 1932, Thomas et al. 1995, Woods & Ramsay 2007). In the case
of the glucose-insulin regulatory system, it is the glucose level that is the regu-
lator variable and the insulin level is the effector variable (Fossion et al. 2018).
Indeed, glucose levels should be maintained between 72 − 99 mg/dl under fasting
conditions (National Institute for Clinical Excellence 2012), while the insulin levels
should vary between 0 − 30 mU/l (Kraft et al. 1975). Fasting levels of glucose be-
tween 99−124 mg/dl indicate a high risk of diabetes (National Institute for Clinical
Excellence 2012).
While it can be argued that there are 5 clusters of diabetes (Ahlqvist et al. 2018),
it is generally accepted that there are two main types: type 1 diabetes (T1DM); and
type 2 diabetes (T2DM) (Centers for Disease Control and Prevention et al. 2011).
T1DM is a condition where the β-cells in the pancreas are destroyed, almost com-
pletely removing the body's ability to secrete insulin (World Health Organization
et al. 1999, NHS 2014). This destruction of β-cells is usually considered the result
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of an autoimmune process (American Diabetes Association 2014), although in some
T1DM patients there is no evidence of an autoimmune disorder (World Health Or-
ganization et al. 1999, Ahlqvist et al. 2018). Either way, it is a lifelong condition and
cannot currently be prevented. In the UK, there are approximately 369, 000 people
who have been diagnosed with T1DM (Diabetes UK 2017). T2DM is where the
muscle cells start to become insulin resistant, hindering the body's ability to utilise
glucose correctly (NHS 2014). Unlike T1DM, approximately three fifths of cases
of T2DM can be prevented or at least delayed (Diabetes UK 2018). However, this
form of diabetes is more common than T1DM, accounting for around 90% of cases
in the UK (Diabetes UK 2017). Furthermore, it is estimated that almost 1 million
people in the UK have T2DM, but have not yet been diagnosed (Diabetes UK 2017).
Initially, diabetes mellitus causes hyperglycaemia and diabetic ketoacidosis, and
can lead to many other long term health problems, such as, retinopathy, cardio-
vascular disease, nephropathy and neuropathy (Centers for Disease Control and
Prevention et al. 2011). This makes it a significant financial burden, costing the
NHS £9.8 bn in 2010/2011 (Hex et al. 2012). It also accounted for a further £13.9
bn in indirect costs (e.g. social and productivity costs) (Hex et al. 2012). These
costs are expected to increase to £16.9 bn and £22.9 bn respectively in 2035/2036
(Hex et al. 2012). Furthermore, it was predicted by Mathers & Loncar (2006) to in-
crease from the 11th to the 7th leading cause of death in the world by the year 2030.
In reality, it had reached this milestone by 2016 (World Health Organization 2016).
1.3 Ultradian oscillations
Within the glucose-insulin regulatory system, both rapid (period ≈ 6-15 minutes)
and ultradian (period ≈ 80-180 minutes) oscillations of insulin have been observed
(Satin et al. 2015), along with glucose oscillations (period ≈ 80-150 minutes) that
are tightly coupled to the insulin oscillations of similar period (Scheen et al. 1996).
These ultradian oscillations were first observed by Hansen (1923) and have been
observed during fasting (O’Meara et al. 1993), meal ingestion, continuous enteral
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nutrition, and under a constant glucose infusion (Simon & Brandenberger 2002).
As was highlighted by O’Meara et al. (1993), insulin resistance leads to a lack
of control of the ultradian rhythms in the glucose-insulin regulatory system, with
the main effect of dampening the oscillations (Fig. 1.1). Indeed, when under the
effect of a constant glucose infusion, the absolute amplitude of the insulin levels
declines when moving from a group of patients without diabetes to patients with
T2DM (O’Meara et al. 1993). Although the role of ultradian rhythms is not fully
understood, there exists clinical evidence that an oscillatory insulin secretion is more
efficient in managing a sustained glucose stimulation than a continuous one (Sturis
et al. 1995). It is worth mentioning that ultradian rhythms are also found in other
endocrine systems such as the hypothalamic pituitary adrenal (HPA) axis, which is
responsible for the secretion of cortisol (Walker, Terry & Lightman 2010). In this
system, it has also been demonstrated that rhythmic secretion improves the reaction
to stress (Lightman et al. 2008).
A current hypothesis for explaining the advantages conferred by oscillatory reg-
ulation is the avoidance of downregulation (Walker et al. 2010), in which signalling
receptors would become exhausted when submitted to a constant stress. As such,
oscillations offer a more sustainable response to a continuous stimulus, periodically
reducing the load on receptors and enabling their replenishment.
The consideration of these rhythms is currently not embedded in the diagnostic or
treatment of diabetes. Therapies for diabetic individuals typically focus on keeping
glucose levels within an acceptable range using a variety of medical strategies.
1.4 Aims and objectives
In this thesis, we aim to investigate the impact of deficiencies in either the pancreatic
insulin secretion or glucose utilisation on the production of ultradian oscillations in
the glucose-insulin regulatory system through the use of two mathematical models.
Indeed, the primary focus will be on the stability analysis of models of ultradian
rhythms, which are based on a system of first order nonlinear differential equations
with multiple time delays. The sensitivity of the regulation in the time-delay domain
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Figure 1.1: Profiles of the glucose and insulin blood concentrations for a non-diabetic
(left) and a T2DM patient (right) under a constant glucose infusion. Figure from
O’Meara et al. (1993).
with respect to various physiological parameters will be explored analytically and
numerically. This will permit the introduction of measurable indicators of deficiency
in the system as well as a description of the contribution of clinical treatments to
reintroducing the oscillatory behaviour. Furthermore, a perturbation of periodic
solutions in the reduced model will be explored in order to investigate the effect of
model parameters on the amplitude and period of the oscillations.
1.4.1 Proposed questions
The primary questions we address in this project are:
What is the effect of reduced insulin production and/or sensitivity on the
ultradian rhythms in an individual and what mechanisms can be used
to restore the ultradian oscillatory regime to an acceptable physiological
behaviour?
What is the effect of diabetic parameters on the amplitude and period of
the ultradian rhythms?
1.4.2 Motivation
One of the main queries (see Atkinson, Eisenbarth & Michels (2014, p. 13) for a
detailed list) regarding the treatment of diabetes is:
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“Can a safe and effective closed-loop therapy system be developed?”
A closed-loop therapy system is a system that combines a glucose sensor, a con-
trol algorithm (based around a mathematical model), and an insulin infusion device
(Cobelli, Renard & Kovatchev 2011). This type of system is most commonly referred
to as an artificial pancreas (AP). The end aim of the AP is to fully automate/regulate
glucose control, with the result of delaying (or preventing) the complications of di-
abetes, lowering the risk of hyperglycaemic episodes, and reducing the time spent
and discomfort of multiple daily insulin injections and glucose tests (Jaremko &
Rorstad 1998). In its current state, the AP may decrease the number of extreme
variations in the blood glucose by calculating the optimal doses of insulin to be
administered (Turksoy & Cinar 2015). As it stands, one of the main challenges in
creating a safe and effective AP is the (commercial) integration of high tech contin-
uous glucose monitors (CGM) and insulin infusion systems, along with closed-loop
algorithms (Peyser et al. 2014). The algorithms must be able to accurately main-
tain normoglycemia, by ordering just the right amount of insulin, while adjusting
for inaccuracies in the glucose data (Jaremko & Rorstad 1998). To accelerate the
development of the AP, a suitable mathematical model which can be used as the
basis of the control algorithm needs to be developed and made widely available (Steil
& Reifman 2009, Cobelli et al. 2011).
Why modelling is important
Along with the need as the basis of a control algorithm in an AP, a dynamical
mathematical model which takes into account several important physiological fea-
tures of this system, as well as the various delays in the reactions, has been shown
to be important in the precise description of the glucose-insulin oscillations (Sturis
et al. 1991, Tolic, Mosekilde & Sturis 2000, Li, Kuang & Mason 2006). Through
analytical characterisation of the favourable conditions leading to the onset of an
oscillatory regime in an appropriate mathematical model, the underlying mecha-
nisms which are most responsible for this regulation can be highlighted (Ajmera
et al. 2013).
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1.4.3 Methodology
We propose and study two two-compartment nonlinear delay differential equation
(DDE) models for representing the ultradian oscillations which are known to occur
within the glucose-insulin regulatory system. They are based on the one introduced
by Li et al. (2006), which is of the form
d
dt
G(t) = F1 (G(t), I(t), I(t− τ2), β) , (1.4.1)
d
dt
I(t) = F2 (G(t), G(t− τ1), I(t), α) ,
where G(t) and I(t) represent the glucose and insulin blood levels respectively,
τ1, τ2 > 0 are discrete delays within the system, and α and β represent deficien-
cies in the glucose-insulin regulatory system (see Section 3.1 for a more in-depth
description). The steady state is defined as the equilibrium point in the state space
for which G(t) = G¯, I(t) = I¯ satisfies F1
(
G¯, I¯, β
)
= 0, F2
(
G¯, I¯, α
)
= 0 and thus
depends on the parameters α and β. Hence, the effect of the diabetic parameters on
the steady state of the system is then described. Next, a linear stability analysis is
performed by noting that system (1.4.1) can be linearised as follows to characterise
the nature of the equilibrium u˙
v˙
 =
 ∂F1∂X(t) ∂F1∂Y (t)
∂F2
∂X(t)
∂F2
∂Y (t)
∣∣∣∣
X(t)=X¯,Y (t)=Y¯
 u(t)
v(t)

+
 ∂F1∂X(t−τ1) ∂F1∂Y (t−τ1)
∂F2
∂X(t−τ1)
∂F2
∂Y (t−τ1)
∣∣∣∣
X(t−τ1)=X¯,Y (t−τ1)=Y¯
 u(t− τ1)
v(t− τ1)

+
 ∂F1∂X(t−τ2) ∂F1∂Y (t−τ2)
∂F2
∂X(t−τ2)
∂F2
∂Y (t−τ2)
∣∣∣∣
X(t−τ2)=X¯,Y (t−τ2)=Y¯
 u(t− τ2)
v(t− τ2)
 , (1.4.2)
where u(t) = X(t)− X¯, v(t) = Y (t)− Y¯ . By looking for exponential solutions i.e. u(t)
v(t)
 =
 u0
v0
 eλt,
a transcendental characteristic equation of the form
λ2 + Aλ+B + Ce−λτ1 +De−λ(τ1+τ2) = 0, (1.4.3)
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is found. Here A,B,C,D are functions of the model parameters. This is then used
to investigate the stability of the system with respect to the diabetic parameters (see
Section 3.1.2). Additionally, due to the existence of a curve of supercritical Hopf
bifurcations in the (τ1, τ2) space, the characteristic equation is used to mathemati-
cally investigate treatment strategies for restoring oscillations within the system by
looking at the location of its rightmost eigenvalue (Section 4.2). Indeed, it is known
that quasi-polynomials of the form (1.4.3) only possess a finite number of roots in
the right half-plane (see, e.g. Smith (2011, pp. 17)). It is also shown that pairs of
purely imaginary roots of (1.4.3) can be characterised using Chebyshev polynomials
(Section 3.2.1).
Finally, a Poincare´-Lindstedt (P-L) perturbation method is applied to investigate
the effect of model parameters on the amplitude and frequency of periodic solu-
tions in a reduced nonlinear polynomial model. Indeed, by removing long term
non-periodic variation (secular terms) through the rescaling of time, the periodic
solutions can be studied in more depth (Casal & Freedman 1980). Initially, the hep-
atic glucose production term is considered constant, i.e., only one delay is present.
Then by assuming τ2 = kτ1 with k ∈ Z+, that is, that τ2 is commensurate with τ1,
the method is applied to the reduced model with a linear hepatic term. See Chapter
5 for more details.
1.4.4 Statement of original contribution
• A local stability analysis is used to investigate the effect of diabetic parameters
on the stability of a two delay model of the glucose-insulin regulatory system.
• The restoration of an oscillatory regime within the system is explored mathe-
matically using four treatment strategies.
• Analytical expressions for the amplitude and period of the ultradian rhythms
are obtained.
As mentioned in the preamble, some of the material presented in this thesis, namely
parts of Sections 1.3, 1.4.1, 3.1, and 3.3, as well as elements of Chapters 4 and 6, is
based on Huard, Bridgewater & Angelova (2017).
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1.5 Thesis structure
Chapters 2 - 5 of this thesis focus on the mathematical modelling of the glucose-
insulin regulatory system using DDEs. More specifically, Chapter 2 highlights key
existing literature in the modelling of glucose and insulin dynamics. In Chapter
3, two two-compartment DDE models are introduced, and analysed using a local
stability analysis. Chapter 4 investigates the use of four treatment strategies in the
restoration of the ultradian oscillations. In Chapter 5, analytical expressions for the
amplitude and period of the periodic solutions in the simplified non-linear model are
obtained. Finally, in Chapter 6 a conclusion for the work is presented, and possible
future avenues are explored.
Chapter 2
Mathematical modelling of
glucose-insulin regulation: an
overview
Mathematical modelling and computer simulation have become a key means for
researchers to investigate and develop new understandings of biological processes
(Barnes & Chu 2015). Indeed, mathematical models have been used to describe
and investigate a variety of biological concepts and systems, for example: dynamics
of infectious diseases (Anderson & May 1992); tumour growth (Roose et al. 2007);
epilepsy (Lytton 2008); and the HPA axis (Rankin et al. 2012). With regards to
the glucose-insulin regulatory system, it is known that the mathematical modelling
of diabetes enables a deeper understanding of the underlying mechanisms involved
(Ajmera et al. 2013).
In this chapter, existing models of the glucose-insulin regulatory system are
discussed. As highlighted by Boutayeb & Chetouani (2006), there exists a breadth
of literature on the modelling of the subject. Indeed, models of the glucose-insulin
system can be broken down into many categories, such as: whole body glucose-
insulin dynamics (Boutayeb & Chetouani 2006, Ajmera et al. 2013); glucose-insulin
oscillations (Palumbo et al. 2013); insulin release (Ajmera et al. 2013); and diagnosis
(Ajmera et al. 2013). They can also be grouped mathematically, for example as:
ordinary differential equations (ODEs); delay differential equations (DDEs); and
10
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stochastic differential equations (SDEs) (see Makroglou, Li & Kuang (2006) for a
detailed list). Therefore, the aim of this chapter is not to provide an exhaustive
overview of the available models, but rather the background for which the models
presented in Chapter 3 are based. Hence, the primary focus will be on the review of
existing models of the ultradian oscillations in the glucose-insulin regulatory system.
2.1 Non-oscillatory models of the glucose-insulin
system
Here, we give a brief overview of glucose-insulin models in which: (1) no oscillations
are produced; or (2) oscillations are not the primary focus of the model. While some
of these models will not directly influence the formulation of the models presented in
Chapter 3, their relevance in the field of diabetic modelling warrants their inclusion.
2.1.1 Minimal model
According to Derouich & Boutayeb (2002), Bolie (1961) was one of the pioneer-
ing papers in glucose-insulin regulation modelling, and many mathematical models
have been proposed since in order to help understand the mechanisms within the
system (Makroglou et al. 2006). One of the most commonly used models in research
(De Gaetano & Arino 2000, Bergman 2005, Cobelli et al. 2011), is Bergman’s mini-
mal model (Bergman et al. 1979), which is an ODE model with two compartments.
It is given by the following equations (Bergman 2005)
dG(t)
dt
= − (SG −X(t))G(t),
dX(t)
dt
= p2I(t)− p3X(t),
where G(t) is the plasma glucose concentration, X(t) is the remote insulin (i.e.
insulin in the interstitial fluid (Bergman 2005)) , I(t) is the plasma insulin con-
centration, p2 represents the fractional rate at which insulin appears in the inter-
stitial fluid, p3 represents the rate at which insulin is cleared from interstitial fluid
and SG represents the effectiveness of glucose (Bergman 2005). Each of the pa-
rameters can be measured using the intravenous glucose tolerance test (IVGTT)
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(Bergman et al. 1979). By looking at the partial derivative of I(t) and G(t) upon
dG
dt
(Bergman 2005), the insulin sensitivity index (Bergman et al. 1979), SI , was
defined as
SI =
p3
p2
.
This has enabled estimates of the insulin sensitivity to be calculated using the
IVGTT rather than the more invasive glucose clamp method (Bergman et al. 1979).
Bergman (2005) indicates that the minimal model’s long use in clinical trials may
be attributed to its simplicity, and robustness. While possible flaws have been high-
lighted by some authors (De Gaetano & Arino 2000, Makroglou et al. 2006), its
importance in physiological research for diabetic research is strongly acknowledged.
However, due to the fact that it does not lead to oscillations, Bergman’s minimal
model will not be used in the formulation of the models introduced in Chapter 3.
2.1.2 Further models of the IVGTT
De Gaetano & Arino (2000) proposed the following DDE model for representing
plasma glucose G(t) and insulin I(t) dynamics
dG(t)
dt
= −b1G(t)− b4G(t)I(t) + b7, dI(t)
dt
= −b2I(t) + b6
b5
∫ t
t−b5
G(s)ds, (2.1.1)
with
G(0) = Gb + b0, I(0) = Ib + b0b3, and G(t) = Gb, t ∈ [−b5, 0),
where the coefficients are defined as
Gb : Pre-intravenous glucose bolus plasma glucose concentration.
b0 : Theoretical increase in plasma glucose after the intravenous glucose bolus.
b1 : Glucose effectiveness.
b2 : Rate of insulin degradation.
b3 : Insulin concentration increase due to the intravenous glucose bolus.
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b4 : Insulin sensitivity/resistance.
b5 : Time delay in insulin secretion.
b6 : Glucose stimulated maximal insulin secretion.
b7 : Hepatic glucose production.
The solutions of the model were shown to be positive, bounded, and globally asymp-
totically stable around a unique steady state (De Gaetano & Arino 2000). Li, Kuang
& Li (2001) generalised the model of De Gaetano & Arino (2000) as follows
dG(t)
dt
= −f (G(t))− g (G(t), I(t)) + b7, dI(t)
dt
= q (L(Gt))− p (I(t)) ,
where f(G(t)) is the insulin independent glucose uptake, g(G(t), I(t)) represents
the insulin dependent glucose utilisation, p(I(t)) represents the insulin degradation,
and q(L(Gt)) is the insulin secretion stimulated by glucose. Two types of delay
were considered in the process of insulin secretion, discrete and distributed. In both
cases it was shown that a Hopf bifurcation occurs, although it should be noted that
for a physiological choice of parameters that the solutions were always in the stable
regime (Li et al. 2001). Further developing the minimal model, Panunzi, Palumbo
& De Gaetano (2007) introduced a single delay model based on (2.1.1), with the
ranges of the delay being explored by Li et al. (2012). More recently, Shi et al.
(2017) introduced a IVGTT model with a delayed effect in the past sub-interval
centered at t− τ with radius . This delayed effect represented the delay of glucose
stimulated insulin secretion. The model is given as follows
dG(t)
dt
= b− SgG(t)− SiG(t)I(t), dI(t)
dt
= σf
(
1
2
∫ −τ+
−τ−
G(t+ θ)dθ
)
− diI(t),
with
f(z) =
zn
zn + αn
for z, α ≥ 0 and n ≥ 2, G(t) = φ(t), t ∈ [−τ − , 0],
where b, Sg, Si, σ and di > 0 are parameters representing the hepatic glucose pro-
duction, insulin independent glucose utilisation, insulin sensitivity/resistance, rate
of insulin secretion stimulated by glucose and insulin degradation rate, respectively.
Depending on the values of τ and  it was shown that the system could switch from
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stable to unstable (Shi et al. 2017). Indeed, using parameter estimates based on
patient data, it was numerically shown that a smooth monotonic curve of Hopf bi-
furcation points split the (τ, ) plane into two regions, one in which the equilibrium
point was stable, and one where the limit cycle existed (Shi et al. 2017). However,
the values of τ and  required to generate the limit cycle were considered to be
non-physiological (Shi et al. 2017) and hence, as with the previous models discussed
in this section, stable solutions are predicted when using physiological meaningful
parameter values (Shi et al. 2017).
2.2 Models of the ultradian rhythms
Many biological systems are modelled by autonomous systems without delay (Thomas
et al. 1995). However, the use of delays is often justified in realistically replicating
core aspects of these systems (Thomas et al. 1995). Indeed, models with delays are
largely accepted as a source of instabilities and periodic oscillations (Bocharov &
Rihan 2000). In this section, first ODE models of the ultradian oscillations in the
glucose-insulin system are explored. While the models do not contain explicit delays,
subsystems are used to replicate delayed effects. Next, DDE models of the ultra-
dian rhythms are studied. Finally, models that are used to investigate treatment
strategies and that can replicate the ultradian oscillations are highlighted.
2.2.1 ODE models
In a pioneering series of clinical investigations of ultradian oscillations conducted in
the early 1990s, Sturis et al. (1991) designed the following three compartment ODE
model that was based on two negative feedback loops in the glucose-insulin system
dx
dt
= f1(z)− E
(
x
V1
− y
V2
)
− x
t1
,
dy
dt
= E
(
x
V1
− y
V2
)
− y
t2
,
dz
dt
= f5(h3) + I − f2(z)− f3(z)f4(y),
dh1
dt
= 3
(
x− h1
t3
)
,
dh2
dt
= 3
(
h1 − h2
t3
)
,
dh3
dt
= 3
(
h2 − h3
t3
)
,
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where x(t), y(t) and z(t) are the plasma insulin, insulin in the interstitial fluid,
and mass of glucose, respectively. The two delays in the system are the insulin
production delay, and the hepatic glucose production delay, which are represented
by the separation of the insulin into two compartments and the three-tiered system
of auxiliary variables, h1, h2 and h3, respectively. The functions f1 to f5 are given
by
f1(G) =
Rm
1 + e
C1−GV−1g
a1
, f2(G) = Ub
(
1− e− −GC2Vg
)
, f3(G) =
G
C3Vg
,
f4(I) = U0 +
Um − U0
1 + e
−β log
(
I
C4(V−1i +(Eti)−1)
) , f5(I) = Rg
1 + eα(IV
−1
p −C5)
,
where f1 is the pancreatic insulin production, f2 and f3f4 are the glucose utilisation
by the brain, and muscle/fat cells, respectively, and f5 is the hepatic glucose pro-
duction. The values of the parameters in the functions f1−f5 are given in Tables 2.1
and 3.2. For more details regarding the formulation of these functions, see Section
Constant Value Units
a1 300 mg/l
C1 2000 mg/l
C2 144 mg/l
C4 80 mU/l
C5 26 mU/l
α 0.29 lm/U
β 1.77
Table 2.1: Parameters used in the functions f1 − f5. They were originally deter-
mined by fitting the functions f1 - f5 to published clinical experiments of individual
subsystems (see Sturis et al. (1991) and references therein).
3.1.
Ultradian insulin secretion oscillations were reproduced using the model, and this
led to the proposition that there is no need to postulate the existence of an intra-
pancreatic pacemaker (Sturis et al. 1991). The model was later simplified by Tolic
et al. (2000).
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2.2.2 DDE models
The model of Sturis et al. (1991) has become the basis of multiple DDE models
(Drozdov & Khanina 1995, Engelborghs et al. 2001, Bennett & Gourley 2004a).
Indeed, Li et al. (2006) proposed the following two compartment DDE model incor-
porating two time delays
dG(t)
dt
= Gin − f2 (G(t))− f3(G(t))f4(I(t)) + f5(I(t− τ2)),
dI(t)
dt
= f1(G(t− τ1))− diI(t),
where the functions f1−f5 are as defined by Sturis et al. (1991). The two delays, τ1
and τ2, can be interpreted as the time taken for an elevated glucose concentration
to stimulate insulin release and be transported to the interstitial space, and the
time taken for insulin to have an observed effect on the liver, respectively (Li et al.
2006). It is important to note that the incorporation of the delay in hepatic glucose
production was originally based on observed data, rather than from a physiological
perspective. Indeed, a suitable method to estimate and study the effect of the delays
on the endocrine system does not yet exist (Wu et al. 2011). However, they remain
physiologically plausible, and from a mathematical perspective they are crucial in
the production of an oscillatory regime (Li et al. 2006). Li & Kuang (2007) studied
the model in more depth analytically, and then Song, Huang & Li (2014) adapted
the model in order to be incorporated within an AP, through the addition of external
insulin at regular time intervals. Analytical characterisation of this adapted model
led to an inequality for ensuring periodic solutions within the system.
In Huard et al. (2015), the models proposed by Sturis et al. (1991) and Li et al.
(2006) were further developed through the introduction of Hill equations to model
the functions f1, f2, f4 and f5, all of which represent crucial features of the regulatory
system. This enabled the use of parameters within the model that have physiological
meaning (Huard et al. 2015). These parameters were then related to the apparition
of an oscillatory regime. A further analytical characterisation of the two-delay model
was also carried out, through an analysis of its local and global stability properties
using a Lyapunov functional, thus extending the results obtained by Bennett &
Gourley (2004b) to the two-delay case.
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2.2.3 Modelling the effect of diabetes
To model the dynamics of insulin therapies in T1DM patients, Wang, Li & Kuang
(2007) proposed the following DDE model
dG(t)
dt
=Gin(t)− f2 (G(t))− f3 (G(t)) f4 (I(t− τ3)) + f5 (I(t− τ2)) ,
dI(t)
dt
=Iin(t)− diI(t),
where the functions f1− f5, are as defined by Sturis et al. (1991), τ2 is as defined by
Li et al. (2006), and Gin(t) and Iin(t) are positive ω-periodic functions representing
glucose and insulin infusions, respectively. τ3 is defined as the time taken for insulin-
dependent glucose utilisation by the cells to occur. The effects of different types
of insulin were explored. Due to the periodicity of the two infusions, a unique and
globally asymptotically stable solution (G(t), I(t)) was always shown to exist. Chen,
Tsai & Wong (2010) introduced the following model to extend the model developed
by Li et al. (2006)
dG(t)
dt
=[Gin(t) + f5 (I(t− θ2)) f6 (G(t))]
− [f2 (G(t)) + f7 (G(t)− 330) + βf3 (G(t)) f4 (I(t))],
dI(t)
dt
=αf1 (G(t− θ1))− diI(t),
where f6(G(t)) and f7 (G(t)− 330) are functions used to model the effects of hy-
perglycaemia, θ1 and θ2 correspond to the delays defined by Li et al. (2006), and
Gin(t) is a variable glucose infusion to model food uptake. The functions f1 − f5
are as defined by Sturis et al. (1991), and the parameters α, β represent insulin
release from the pancreas and insulin resistance, respectively. The effect of these
parameters on the oscillatory regime was explored numerically.
Kissler et al. (2014) proposed the following two-delay model, which features
Michaelis-Menten dynamics for quantifying the insulin degradation
dG(t)
dt
=Gin + f5 (I(t− τ2))− f2 (G(t))− γ[1 + s(m−mb)]f3 (G(t)) f4 (I(t)) ,
dI(t)
dt
=Iin + βf1 (G(t− τ1))− VmaxI(t)
KM + I(t)
,
where the functions f1− f5, are as defined by Sturis et al. (1991), and τ1 and τ2 are
as defined by Li et al. (2006). The constants β and γ represent β-cell function and
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insulin resistance, respectively. As in Chen et al. (2010), these parameters reflecting
the effect of diabetes ranged between 0 and 1. The model was used to investigate
personalised treatment options for diabetics. While the authors noted whether the
resulting solution was oscillatory, the restoration of an oscillatory regime was not
the focus of the work.
Chapter 3
Models of glucose-insulin
regulation
This chapter focuses on the delayed models of ultradian glucose-insulin regulation
which form the core of our investigations. Firstly, the most general form of the
two-delay model is presented along with a description of the main physiological
functions entering the system. Then, local stability analysis is used to investigate
the contribution of various parameters on the oscillatory behaviour of the model,
with a special emphasis on the effect of insulin resistance. Secondly, a simplified
polynomial version of the first model is introduced to facilitate the characterisation of
the periodic solutions. Conditions for stability are identified through local stability
analysis and it is shown that points of Hopf bifurcations can be investigated using
Chebyshev polynomials. Finally, the periodic solutions of a third (linear) model, in
which a non delayed, glucose stimulated, insulin response is included, are explored.
3.1 The two-delay model
In its most general form, the model proposed is given by the following system of
DDEs with two delays
G˙ = Gin − f2(G)− βf3(G)f4(I) + γf5(I(t− τ2)), (3.1.1)
I˙ = Iin + αf1(G(t− τ1))− di(α, β)I,
19
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and it is based on the framework represented in Fig. 3.1. Here G(t) and I(t) repre-
sent plasma glucose and plasma insulin concentrations in mg and mU , respectively.
Note, for the purpose of all Figures, G(t) and I(t) will be converted to mg/dl and
mU/l, respectively. Model (3.1.1) follows the ones introduced by Kissler et al. (2014)
and Huard et al. (2015), which were based on the works of Sturis et al. (1991), Tolic
et al. (2000), Engelborghs et al. (2001), Bennett & Gourley (2004a), and Li et al.
(2006). Indeed, as in Kissler et al. (2014), model (3.1.1) incorporates parameters for
insulin resistance and insulin secretion capacity, as well as the use of Hill functions
for system functions, as done by Huard et al. (2015). In contrast to the models of
Kissler et al. (2014) and Huard et al. (2015), it incorporates a parameter for the
effect of medication on the hepatic glucose production. Additionally, it takes the
degradation term to be a function of the insulin resistance and insulin secretion
capacity.
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Figure 3.1: Flow diagram for model (3.1.1).
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The relevant features of the model can be summarised as follows.
αf1(G(t− τ1)) : Insulin production/secretion. It is represented by a sigmoidal
function (Grodsky 1972) (Fig. 3.2a). A delay τ1 is present in this process. It
accounts for the time lag, in minutes, between when high glucose levels trigger
the production of insulin within the pancreas and when it becomes available
(Li et al. 2006). Clinical experiments have provided a time range of [5, 20]
minutes for this reaction. The parameter α modulates this secretion, with low
levels being typical of T1DM.
f2(G) : Insulin-independent glucose utilisation, mainly by the brain. As seen in
Fig. 3.2b it is also sigmoidal and is based on the function used by Turner et al.
(1979).
βf3(G)f4(I) : Insulin-dependent glucose utilisation, by the muscles. As in Sturis
et al. (1991), f3(G) is linear (Fig. 3.2c) and f4(I) is sigmoidal (Fig. 3.2d).
Values of β < 1 indicate a reduced capacity of utilising insulin to degrade
glucose, also called insulin resistance, which is seen in T2DM.
γf5(I(t− τ2)) : Glucose production by the liver. The shape of the function is based
on the work of Rizza, Mandarino & Gerich (1981) and can be seen in Fig.
3.2e. Indeed, large values of insulin induce an inhibitory effect on the glucose
production, whereas glucose output increases at lower insulin concentrations
(Rizza et al. 1981). The delay in this reaction, denoted by τ2, denotes the time
between hepatic glucose production and insulin stimulation and is typically
between 20 and 50 minutes (Li et al. 2006). This production is controlled by
the parameter γ, to account for effect of biguanide medications which act by
lowering it to keep glucose levels low (Hundal et al. 2000).
di(α, β) : Combined rate of degradation of insulin, especially by the liver and
kidneys. In Chapter 4, we consider it as a combination of natural (for ex-
ample, exercise (Tuominen, Ebeling & Koivisto 1997)) and artificial (for ex-
ample, through the inhibition of insulin degrading enzyme (IDE) (Costes &
Butler 2014, Maianti et al. 2014)) mechanisms, and as a function of α and β
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to investigate how it can be used to compensate for the effects of a reduced in-
sulin secretion (α) and/or an increased insulin resistance (β) on an appropriate
oscillatory regime.
Here, we represent these functions in terms of Hill functions,
f1 =
Rm(G/Vg)
h1
(G/Vg)h1 + k
h1
1
, f2 =
Ub(G/Vg)
h2
(G/Vg)h2 + k
h2
2
, f3 =
G
C3Vg
, (3.1.2)
f4 = U0 + (Um − U0) [(1/Vi + 1/(Eti))I]
h4
[(1/Vi + 1/(Eti))I]
h4 + kh44
, f5 = Rg
(I/Vp)
h5
(I/Vp)h5 + k
h5
5
,
as defined by Huard et al. (2015). This gives the advantage of introducing new
parameters in the model which bear physiological meaning (a list of which can be
found in Tables 3.1 and 3.2), and hence allows for more adequate modelling of the
underlying physiological dynamics of the glucose-insulin system (Huard et al. 2015).
These values were selected in Huard et al. (2015) to ensure the system produces an
oscillatory regime in a physiologically suitable range for a non-diabetic patient. The
functions are all strictly positive and f1, f2, f4 are increasing while f5 is decreasing.
Here the parameters α and β play a crucial role in modelling the capacity of an
individual to produce insulin or use it to utilise glucose, respectively. Values of
α = β = γ = 1 represent an optimal non-diabetic patient. Therefore, a value of
α < 1 represents a reduced insulin production capability, which is seen in T1DM
(NHS 2014) (as well as after the onset of T2DM (Pories & Dohm 2012)). A value
greater than 1 implies an increased insulin production capacity, observed in the very
early stages of T2DM (although the reason for its occurrence is debated (Pories &
Dohm 2012)). Likewise, if β is smaller than 1, this indicates a reduced insulin-
dependent glucose utilisation which is typical of insulin resistance and related to
both T1DM and T2DM (Greenbaum 2002). A value greater than 1 represents an
increased sensitivity to insulin, which can pose the risk of hypoglycaemia in T1DM.
Finally, values of γ < 1 represent a reduced glucose hepatic production which can
result from the usage of drugs such as Metformin (Hundal et al. 2000), while γ = 1
corresponds to a typical non-diabetic production. For these reasons, the coefficients
α, β and γ will be referred to as the diabetic parameters.
The constant value of Gin is typically between 1 - 3 mg/dl min, a range where
ultradian oscillations have been observed (Simon & Brandenberger 2002). As seen
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(a) Pancreatic insulin secretion function,
f1.
(b) Insulin independent glucose utilisa-
tion, f2.
(c) Insulin dependent glucose utilisation,
f3.
(d) Insulin dependent glucose utilisation,
f4.
(e) Hepatic glucose production, f5.
Figure 3.2: Functional forms of f1, f2, f3, f4 and f5, using the parameter values
given in Tables 3.1 and 3.2.
in Fig. 3.3, solutions to system (3.1.1) when α = β = γ = 1, Iin = 0 and τ1 =
6, τ2 = 36 are oscillatory. Indeed, the joint role of the physiological delays in
producing oscillations in the non-diabetic case has already been highlighted (Li &
Kuang 2007, Huard et al. 2015). As was shown by Li & Kuang (2007), for any τ1 > 0
there exists a τ2 such that the system undergoes a supercritical Hopf bifurcation at
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Hill coefficient Value Hill coefficient Value
h1 2 k1 5830
h2 1.8 k2 103.5
h4 1.5 k4 80
h5 -8.5 k5 26.72
Table 3.1: Values used for the Hill coefficients hi, ki, taken from (Huard et al. 2015).
Constant Value Units Constant Value Units
Rm 210 mU/min Vi 11 l
Vg 10 l E 0.2 l/min
Ub 72 mg/min ti 100 min
C3 1000 mg/l Rg 180 mg/min
U0 40 mg/min Vp 3 l
Um 940 mg/min Gin 1.35 mg/dl min
Table 3.2: Parameters used in model (3.1.1). They were originally determined by
fitting the functions f1 - f5 to published clinical experiments of individual subsystems
(see Sturis et al. (1991) and references therein).
the point (τ1, τ2). This situation is illustrated in Fig. 3.4, where the threshold
curve corresponds to the points where the system possesses a pair of pure imaginary
eigenvalues.
3.1.1 The effect of insulin resistance on the glucose and in-
sulin levels
In this section, we investigate the effect of the diabetic parameter β on the steady
state (G¯, I¯) of model (3.1.1), which is governed by the following system of algebraic
equations
Gin − f2(G¯)− βf3(G¯)f4(I¯) + γf5(I¯) = 0, (3.1.3)
Iin + αf1(G¯)− di(α, β)I¯ = 0. (3.1.4)
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Figure 3.3: Solution to system 3.1.1 when α = β = γ = 1, with di = 0.06, Gin = 1.35
mg/dl min and τ1 = 6 min, τ2 = 36 min.
To match physiological values, the values for the steady state should fit the
ranges 90 < G¯ < 120 and 25 < I¯ < 40 respectively (Sturis et al. 1991). Given
the assumptions on the functions and the parameters of the model, it can be shown
that this system has a unique solution (see e.g. Bennett & Gourley (2004b)). The
dependence upon β can be made more explicit in the following way. Differentiating
implicitly equations (3.1.3) and (3.1.4) with respect to β leads to the following
expressions
−f ′2(G¯)G¯β − f3(G¯)f4(I¯)− β
(
f ′3(G¯)f4(I¯)G¯β + f3(G¯)f
′
4(I¯)I¯β
)
+ γf ′5(I¯)I¯β = 0,
αf ′1(G¯)G¯β − di(α, β)β I¯ − di(α, β)I¯β = 0,
where the β subscript stands for the derivative. In matrix form, these can be written
as
 −A −(B + C)
D −di(α, β)
 G¯β
I¯β
 =
 f3(G¯)f4(I¯)
di(α, β)β I¯
 , (3.1.5)
where we have introduced the following positive β-dependent quantities
A = f ′2(G¯) + βf
′
3(G¯)f4(I¯), B = βf3(G¯)f
′
4(I¯), C = −γf ′5(I¯), D = αf ′1(G¯),
(3.1.6)
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Figure 3.4: Curve of Hopf bifurcations in the optimal non-diabetic case α = β =
γ = 1, with di = 0.06 and Gin = 1.35 mg/dl min.
with the prime ′ denoting the derivative with respect to the argument. The depen-
dence of these functions on β is illustrated in Fig. 3.5.
Hence,
 G¯β
I¯β
 = 1
∆
 di(α, β)β I¯(B + C)− di(α, β)f3(G¯)f4(I¯)
−Df3(G¯)f4(I¯)− Adi(α, β)β
 , (3.1.7)
with
∆ = Adi(α, β) +D(B + C) > 0.
The location of the system’s steady state is linked to the level of insulin resistance
and the clearance rate. Assuming no correlation between insulin degradation and
insulin resistance, i.e. assuming di is constant, the effect of reduced insulin regulation
capacity on the steady state (G¯, I¯) of system (3.1.1) is depicted in Fig. 3.6.
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Figure 3.5: Graphs of the functions A(β), B(β), C(β), D(β) for parameter values
from Tables 3.1 and 3.2, with di = 0.06 and Iin = 0.
Figure 3.6: Effect on the steady state of reducing insulin production (left) and
reducing insulin-dependent glucose utilisation (right), for di = 0.06. The glucose
and insulin steady states are represented by the blue and red curves, respectively.
This picture is already instructive. As expected, reducing insulin production
(α < 1) leads to lower insulin and higher glucose levels. Additionally, introducing
insulin resistance (or equivalently decreasing β) leads to both higher glucose and
insulin levels, as observed physiologically in the early stages of T2DM (Pories &
Dohm 2012). An investigation of strategies for improving the steady states by
altering di(α, β) will be performed in Section 4.2.3.
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3.1.2 The effect of insulin resistance on the ultradian oscil-
lations
We now look at the effect of β on the production of oscillations in (3.1.1). In Kissler
et al. (2014), the effect of a parameter, representing insulin sensitivity, on the real
part of the dominant eigenvalue of the characteristic equation (for the linearised
system) was investigated numerically. It was observed that larger values of the
insulin sensitivity parameter were more likely to give rise to values of the real part
of the dominant eigenvalue in the right half plane, and hence oscillatory solutions
(Kissler et al. 2014). Here, we take a more analytic approach and look to derive a
constraint such that oscillatory solutions are lost.
The linearisation of system (3.1.1) about (G¯, I¯) is given by
 u˙
v˙
 =
 −A −B
0 −di(α, β)
 u(t)
v(t)
+
 0 0
D 0
 u(t− τ1)
v(t− τ1)

+
 0 −C
0 0
 u(t− τ2)
v(t− τ2)
 . (3.1.8)
A complex exponential solution eλt of system (3.1.8) exists if and only if λ satisfies
the following characteristic quasi-polynomial
(λ+ A)(λ+ di(α, β)) +D
[
Be−λτ1 + Ce−λ(τ1+τ2)
]
= 0, (3.1.9)
where it is important to note that A,B,C,D are functions of β. We now show that
the characteristic equation (3.1.9) implies that the introduction of insulin resistance
leads to the loss of oscillations. To do achieve this, we first note that it has been
shown that (3.1.9) undergoes a supercritical Hopf bifurcation in the (τ1, τ2) space
(Li & Kuang 2007). By defining λ(β) = η(β) + φ(β), it can therefore be seen that
for the oscillations to be lost when insulin resistance is introduced, we must have
that η decreases when β decreases from 1. In other words, we wish to prove that
dη
dβ
∣∣∣
β=1
> 0.
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Splitting the real and imaginary parts of (3.1.9) and differentiating with respect to
β, we get expressions of the type
dφ
dβ
c =
dη
dβ
a+ b,
dφ
dβ
a = −dη
dβ
c− d, (3.1.10)
where we introduced the following definitions
a = 2η + A+ di − τ1e−ητ1BD cosφτ1 − (τ1 + τ2) e−η(τ1+τ2)CD cosφ (τ1 + τ2),
b = Aβη + d
′
iη + (diA)β + e
−ητ1 cosφτ1 (BD)β + e
−η(τ1+τ2) cosφ (τ1 + τ2) (CD)β ,
c = 2φ+ τ1 sinφτ1BDe
−ητ1 + (τ1 + τ2) sinφ (τ1 + τ2)CDe−η(τ1+τ2),
d = φ (Aβ + d
′
i)− e−ητ1 sinφτ1 (BD)β − e−η(τ1+τ2) sinφ (τ1 + τ2) (CD)β .
(3.1.11)
Rearranging equations (3.1.10) and eliminating dφ
dβ
leads to an explicit expression
for dη
dβ
, given by
dη
dβ
= −ab+ cd
a2 + c2
. (3.1.12)
We then obtain the following
Proposition 1 Let λ(β) = η(β) + iφ(β) be a solution of the characteristic equation
(3.1.9). Then dη
dβ
> 0 if and only if ab+ cd < 0, with a, b, c, d as defined in (3.1.11).
We now assume that an oscillatory regulation takes place when β = 1, which
is when the system is in normal regulation. We consider the case on the threshold
curve, that is λ|β=1 = (η + iφ)|β=1 = iω, where ω > 0 satisfies a transcendental
equation. Indeed, setting λ = iω in (3.1.9) and separating the real and imaginary
parts leads to the following equation
cos (τ2ω) =
(ω2 + A2)(ω2 + d2i )−D2(B2 + C2)
2BCD2
, (3.1.13)
while ω can be seen as a function of τ1 through the following transcendental equation
(ω2 + A2)(ω2 + d2i ) +D
2(B2 − C2)
+ 2BD
(
(Adi − ω2) cos(τ1ω)− ω(A+ di) sin(τ1ω)
)
= 0, (3.1.14)
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which can also be expressed as
cos(τ1ω + φ) = −(ω
2 + A2)(ω2 + d2i ) +D
2(B2 − C2)
2BD
, (3.1.15)
with
φ = arctan
(
−ω(A+ di)
Adi − ω2
)
+ 2pi.
Using (3.1.13) and (3.1.15), the critical values of τ1 and τ2 can then be algebraically
calculated simultaneously (Gu et al. 2005, Nguimdo 2018, An et al. 2019).
It can be seen from Fig. 3.7 that dη
dβ
|β=1 > 0 when τ1 is within a physiological range,
between 5 and 20 minutes. Indeed, this implies that η decreases when β decreases
from 1 or, in other words, that the oscillations are lost as β decreases from 1. The
overall effect of β on the production of oscillations can then be seen in Fig. 3.8.
As an example, the distribution of eigenvalues λ in the prototypical case τ1 = 6
and τ2 = 36 is depicted in Fig. 3.9, for cases with (β = 1) and without (β = 0.8)
oscillations. This loss of oscillations with decreased β partly reflects what is observed
physiologically. Indeed, as mentioned in Section 1.3, the loss of amplitude in the
insulin oscillations that occurs with insulin resistance is observed experimentally
(O’Meara et al. 1993). On the other hand, the loss of amplitude in the glucose
oscillations is not directly observed physiologically when a constant glucose infusion
is present (O’Meara et al. 1993). However, the observed decrease of entrainment
of insulin secretion by glucose (O’Meara et al. 1993) can be locally seen through a
stretching of the period, which has also been noted. Therefore, we shall interpret
this loss of oscillations in the model with decreased β as the lack of control observed
in patients with T2DM.
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Figure 3.7: The derivative dη
dβ
as a function of τ1, with parameter values from Tables
3.1 and 3.2, with di = 0.06, Iin = 0 and β = 1. Typical values for τ1 are to be chosen
between 5 and 20 minutes.
Figure 3.8: Effect of insulin resistance on the curve of Hopf bifurcations in the (τ1, τ2)
space.
3.2 Reduced polynomial model
We now formulate a reduced polynomial model which is based on system (3.1.1),
and follows the framework given in Fig. 3.10. It is given by
G˙(t) = a0 − a1G(t)− a2G(t)I(t)− a3I(t− τ2)p, (3.2.16)
I˙(t) = b1G(t− τ1)n − b2I(t), n ∈ 2Z, p ∈ Z+,
3.2. Reduced polynomial model 32
Figure 3.9: Eigenvalues of the linearised system for τ1 = 6, τ2 = 36 and di = 0.06,
when β = 1 (left) and β = 0.8 (right).
where G(t) is the plasma glucose concentration (measured in mg), and I(t) is the
plasma insulin concentration (measured in mU). For the purpose of all Figures, G(t)
and I(t) will be converted to mg/dl and mU/l, respectively. All parameters are as-
sumed to be non-zero, and have units as defined in Table 3.3. The coefficients a1 and
a2 describe the insulin independent and dependent glucose utilisations, respectively.
The term a0 := Gin + C comprises two contributions: Gin, which corresponds to
a constant glucose infusion; and C, which originates from the hepatic glucose pro-
duction. Indeed, as seen in equation (3.1.2), the hepatic glucose production can be
represented by a function of the type
Hepatic ≈ K0
K1 + I(t− τ2)p ≈ C − a3I(t− τ2)
p,
where τ2 corresponds to the time taken for hepatic glucose to have an effect on the
glucose levels. In order to explore the effect of different delay values on the limit
cycle, we take τ2 to be a commensurate delay. In the insulin balance equation,
b1 denotes the insulin production capability of the individual, and b2 the insulin
degradation rate. While the insulin secretion term appears to be unbounded, we
note that
Secretion ≈ G(t− τ1)
n
G(t− τ1)n +Kn2
≈ G(t− τ1)
n
Kn2
= b1G(t− τ1)n,
where τ1 is the time taken for insulin to be released and have an effect on the glucose
levels. Hence, the secretion function is a polynomial approximation of the bounded
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Figure 3.10: Flow diagram for model (3.2.16).
function representing insulin secretion. A consequence of this is that it does not
provide the means to investigate the convergence speed of the trajectories to the
limit cycle. However, it does allow for the accurate study of the amplitude and
period of the periodic solutions, which is the focus of Chapter 5.
3.2.1 Local stability analysis of the reduced model
Constant hepatic glucose production
Here we look to find conditions on the parameter values in the reduced model when
p > 2. Hence, as a second-order approximation, only the constant term of the
hepatic production remains (see (3.2.17)).
G˙(t) = Gin − a1G(t)− a2G(t)I(t) + C,
I˙(t) = b1G(t− τ)n − b2I(t), τ = τ1.
(3.2.17)
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Parameter Units
a0 mg min
−1
a1 min
−1
a2 mU
−1 min−1
a3 mg mU
−p min−1
b1 mU mg
−n min−1
b2 min
−1
τ1 min
τ2 min
Table 3.3: Units for the parameters in model (3.2.16).
This is not to say that the delayed term does not have an effect on the oscillations.
In fact, its role on the production of an oscillatory regime has been highlighted and
made explicit in several studies (Li et al. 2006, Huard et al. 2015). However, in this
model, its impact on the amplitude and period of the oscillations is known to be
much less than that of τ1 (see Fig. 6.1. in Li & Kuang (2007)).
Following the arguments made by Shi et al. (2017), it can be shown that trajectories
of model (3.2.17) are positive and bounded whenever G(0) > 0 and I(0) > 0. Indeed,
the arguments for boundedness and positivity for the solutions of the minimal model
(3.2.17) can be summarised as follows:
1. First, let G(0) = G0 > 0 be a positive initial condition and suppose that ∃
t0 > 0 such that G(t0) = 0. Then, at time t0, we have
G˙(t0) = Gin + C > 0,
which is a contradiction, and hence G(t) is always positive if G0 > 0. Similarly,
letting I(0) = I0 > 0 be a positive initial condition and supposing that ∃ t0 > 0
such that I(t0) = 0 we have
I˙(t0) = b0 + b1G(t0 − τ)n > 0,
which is also a contradiction, and hence I(t) is always positive if I0 > 0.
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2. One can then prove boundedness of G(t) by noting that
G˙(t) ≤ a0 − a1G(t)
since G(t), I(t) > 0. Denoting G(t) = X(t) + a0/a1, this implies that
X˙(t) ≤ −a1X(t) → e−a1t d
dt
(
ea1tX(t)
) ≤ 0,
which in turn leads to
ea1tX(t) ≤ X(0) → G(t) ≤
(
G(0)− a0
a1
)
e−a1t +
a0
a1
.
Therefore
G(t) ≤ G+ = max
{
G(0),
a0
a1
}
<∞,
and hence G(t) is bounded for all t > 0.
3. As G(t) < G+ for all t > 0, the second equation of (3.2.17) implies that
I˙(t) ≤ b1Gn+ − b2I(t)
from which it can be shown that
I(t) ≤ I(0)e−b2t + b1G
n
+
b2
(
1− e−b2t) ≤ I+ = max{I(0), b1Gn+
b2
}
<∞,
thus establishing the boundedness of I(t).
Value of the parameters
Given an oscillatory solution, the inverse problem of choosing parameters in model
(3.2.17) can be addressed in the following way. We note that the system’s steady
state (G¯,I¯) is given by
I¯ =
b1G¯
n
b2
, a2b1
(
G¯
)n+1
+ (a1b2) G¯− a0b2 = 0. (3.2.18)
By Descartes’ rule of signs, (3.2.18) has exactly one positive root for G¯, and so one
can always find a positive (G¯, I¯). Here we assume that the target basal levels can
be identified with the steady state of the system.
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1. It has been shown that the insulin clearance is proportional to the insulin
concentration (Topp et al. 2000, Koschorreck & Gilles 2008). Numerical fitting
procedures have rendered values in the range (0.03, 0.3) (Chen et al. 2010). As
in Li et al. (2006) and Huard et al. (2015), we shall choose an initial value of
b2 = 0.06 for most numerical computations with the reduced model.
2. From the knowledge of b2, the value of b1 is then given by
b1 = b2I¯G¯
−n.
3. The system must be in an oscillatory state. Therefore the delay τ ∈ R+ must
be larger than the critical value τ0 such that the characteristic equation
(λ+ b2)(λ+ a1 + a2I¯) + na2b2I¯e
−λτ0 = 0 (3.2.19)
possesses a set of conjugate purely imaginary root λ = ±iω0. This requirement
implies that ω0 and τ0 satisfy the system
na2b2I¯ cos (ω0τ0) = ω
2
0 − b2(a1 + a2I¯), na2b2I¯ sin (ω0τ0) = (b2 + a1a2I¯)ω0,
(3.2.20)
or equivalently,
cos (ω0τ0) =
ω20 − b2(a1 + a2I¯)
na2b2I¯
, sin (ω0τ0) =
(b2 + a1a2I¯)ω0
na2b2I¯
. (3.2.21)
This in turns implies that ω0 satisfies a quartic equation
ω40 + ω
2
0
(
(a1 + a2I¯)
2 + b22
)
+ b22
((
a1 + a2I¯
)2 − (na2I¯)2) = 0. (3.2.22)
Requiring that equation (3.2.22) possesses a positive root for ω0 gives explicit
conditions on the coefficients for the existence of a Hopf bifurcation. Since the
middle term in (3.2.22) is always positive, one must have
n >
a1
a2I¯
+ 1 > 1,
in order to have a bifurcation. We shall therefore choose n = 2 in all subsequent
calculations, which in turn implies that a1 < a2I¯. The value of τ0 is then
obtained from (3.2.21) as
τ0 =
1
ω0
(
arccos
(
ω20 − b2(a1 + a2I¯)
2a2b1G¯2
)
+ 2Kpi
)
, (3.2.23)
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where K ∈ Z+ is the smallest integer such that (3.2.23) defines a positive value.
Larger values of K gives successive values of τ0 for which stability switches may
occur in the linear system. However, for the nonlinear system (3.2.17), it is
numerically observed that oscillations are present whenever τ ≥ τ0.
For a more robust approach on the restrictions on the parameter n such that
a bifurcation occurs, readers are referred to the next subsection.
4. The constant a0 := Gin + C is obtained from
a0 = a1G¯+ a2G¯I¯.
The parameters a1 and a2 can be chosen such that oscillations are present for
a physiologically relevant value of the critical delay τ0. For different values of
b2, one can numerically compute the range of achievable values for τ0 using
equation (3.2.23). This gives the graph shown in Fig. 3.11.
Figure 3.11: Range of values of τ0 which can be attained by varying a1 and a2 for
each given value of b2. Here, we used the fixed values G¯ = 97.87 mg/dl and I¯ = 30
mU/l. Any value of τ above the range leads to an oscillatory solution.
As observed in Shi et al. (2017), the model leads to slightly higher values of
τ0 than in the two-delay model (3.1.1), although it is comparable with the
value one obtains when formally setting τ2 = 0 in (3.1.1) (see Fig. 3.4 on page
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26). This highlights the importance of both delays in generating a negative
feedback loop. Nevertheless, this approach provides a model able to replicate
the nonlinear oscillations within an appropriate physiological range (Fig. 3.12).
Figure 3.12: Oscillations described by the minimal model (3.2.17) using Parameter
Set 1 from Table 5.1, with a2 = 0.0017.
Stability of the steady state
Here we use the following formulation of Rouche´’s theorem to investigate the con-
ditions needed for stability on the parameter n in (3.2.17).
Theorem 1 (Rouche´’s theorem (Lang 2013)) For two given functions f(z) and
g(z) which are analytic in A, if |f(z)| > |g(z)| on χ, where χ is a simple loop ho-
motopic to a point in A, then f(z) and f(z) + g(z) have the same number of roots
inside χ.
Choosing χ as a semicircle in the right half plane with radius r such that r →∞
(see Fig. 3.13), it is clear that if (3.2.19) has no roots inside χ, then system (3.2.17)
is stable. We then have the following proposition.
Proposition 2 If n = 1, then system (3.2.17) is stable for all a0, a1, a2, b1, b2, τ1 >
0.
Proof. Let us define
f(z) = z2 + (a1 + a2I¯ + b2)z + b2(a1 + a2I¯), g(z) = na2b2I¯e
−zτ0 ,
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Figure 3.13: Simple closed curve, χ, in the complex plane.
with z = η + iφ, η ∈ R+ and φ ∈ R. By Descartes’ rule of signs, we can see that
f(z) has no roots in χ. As f(z) + g(z) = 0 is equivalent to (3.2.19), system (3.2.17)
must be stable if |f(z)| > |g(z)|. Noting that
1. |g(z)| = na2b2I¯|e−ητ0|,
2. |f(z)| = (φ2[a21 + (2a1 + a2I¯ + 2)(a2I¯ + 2) + b2(b2 + 4)]
+ [φ2− η(a1 + a2I¯ + b2 + η)]2 + b2(a1 + a2I¯)[(a1 + a2I¯)(b2 + 2η) + 2η(b2 + η)]) 12 ,
it can be easily seen that the maximum of g(z) and the minimum of f(z) occur
when z = 0. Hence it can be shown that
n < 1 +
a1
a2I¯
leads to |f(z)| > |g(z)|. Therefore, system (3.2.17) is stable for n = 1. 
Extension to commensurate delays
We now consider the problem of characterising periodic solutions in system (3.2.16)
when the delays are assumed to be commensurate, i.e. τ2 = kτ1, with k ∈ Z+.
A straightforward generalisation can be made for the case when the delays are
rationally related. This assumption allows to perform a perturbative analysis of
the periodic solutions, given that the point (τ1, kτ1) remains sufficiently close to the
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threshold curve. Geometrically, this approach provides a discrete set of characteristic
frequencies ω0, corresponding to the intersection between a line and the threshold
curve (see Fig. 3.14). We show that these crossing points can be described by using
linear combinations of Chebyshev polynomials of the first type.
Figure 3.14: Hopf bifurcation curve for model (9) in the space of delays, along with
expansion lines τ2 = kτ1, k ∈ Z+.
In its most general form, the polynomial model with commensurate delay becomes
G˙ = a0 − a1G− a2GI − a3I(t− kτ)p, I˙ = b1G(t− τ)2 − b2I, τ = τ1. (3.2.24)
For a0 > 0, system (3.2.24) always possesses a positive steady state G¯, I¯ which
satisfies
a3b
p
1G¯
2p + a2b1b
p−1
2 G¯
3 + a1b
p
2G¯− a0bp2 = 0, I¯ =
b1
b2
G¯2.
The linearisation about its unique positive steady state reads as X˙
Y˙
 =
 −(a1 + a2I¯) −a2G¯
0 −b2
 X
Y
+
 0 0
2b1G¯ 0
 Xτ
Yτ

+
 0 −a3pI¯p−1
0 0
 Xkτ
Ykτ
 , (3.2.25)
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where Xτ = X(t − τ), Xkτ = X(t − kτ) and similarly for Y . The characteristic
equation of (3.2.25) is a quasi-polynomial of the form
λ2 + A1λ+ A2 + A3e
−λτ + A4e−(k+1)λτ = 0, k ∈ Z+, (3.2.26)
where
A1 = a1 + a2I¯ + b2, A2 = a1b2 + a2b2I¯ , A3 = 2a2b1G¯
2, A4 = 2pG¯I¯
p−1a3b1.
Since A1, A2, A3, A4 > 0, equation (3.2.26) is Hurwitz stable for τ = 0 and so we
now look for conditions on k and τ ensuring that it undergoes a Hopf bifurcation.
Hence, setting λ = iω0, ω0 > 0 leads to the system
ω20 = A2 + A3 cos(ω0τ0) + A4 cos((1 + k)ω0τ0), (3.2.27)
A1ω0 = A3 sin(ω0τ0) + A4 sin((1 + k)ω0τ0). (3.2.28)
Eliminating polynomial occurrences of ω0, one is led to the following trigonometric
equation
A21(A2 + A3 cos (ω0τ0) + A4 cos((1 + k)ω0τ0))
= (A3 sin(ω0τ0) + A4 sin((1 + k)ω0τ0))
2. (3.2.29)
Setting z = cos (ω0τ0), i.e. ω0τ0 = arccos z, then
cos (nω0τ0) = Tn(z), sin (nω0τ0) =
√
1− z2Un−1(z),
where Tn and Un−1 are Chebyshev polynomials of the first and second kinds, respec-
tively. Equation (3.2.29) implies that z satisfies the following polynomial equation
A21(A2 + A3z + A4T1+k(z)) = (1− z2)(A3 + A4Uk(z))2. (3.2.30)
Further using that, for n ≥ m,
(1−z2)Un−1(z) = zTn(z)−Tn+1(z), 2(1−z2)Un−1(z)Um−1(z) = Tn−m(z)−Tn+m(z),
we obtain that (3.2.30) can be rewritten as a linear combination of Chebyshev
polynomials of the first type
A24T2k+2(z) + 2A3A4Tk+2(z) + 2A4A
2
1Tk+1(z)− 2A3A4Tk(z)
+A23T2(z) + 2A
2
1A3T1(z) + 2A2A
2
1 − (A23 + A24) = 0. (3.2.31)
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For a given k ∈ Z+, any real root z of (3.2.31) with |z| < 1 gives a solution for
ω0. The existence of such values of z can be then assessed using Sturm chains and
the fact that Tn(1) = 1, Tn(−1) = (−1)n. From the knowledge of z, one can obtain
ω0 from (3.2.27) and (3.2.28), which can be rewritten as
ω20 = A2 + A3z + A4T1+k(z),
A1ω0 = A3
√
1− z2 + A4
√
1− z2Uk(z). (3.2.32)
Boundedness and persistence
Contrary to the solutions of (3.2.17), solutions to system (3.2.24) may not necessarily
be positive and bounded. Indeed, for certain values of the parameters of the system,
G(t) can be negative and/or unbounded, and I(t) can be unbounded (as illustrated in
Figs. 3.15a, 3.15b and 3.16). Irrespective of this, we have the following proposition.
(a) Positive and bounded solutions of
(3.2.24) with a2 = 0.00009, a3 = 1.415
and p = 1.
(b) Bounded solutions of (3.2.24) with
a2 = 0.00001, a3 = 1.615 and p = 1.
Figure 3.15: Solutions to (3.2.24) with a0 = 285, a1 = 2.02981789884309 × 10−4,
b1 = 9.3× 10−8, b2 = 0.06, τ = 15.8, k = 1, G(0) = 10000 and I(0) = 90.
Proposition 3 Let (G(t), I(t)) be a solution of system (3.2.24). Then I(0) > 0
implies I(t) > 0,∀t > 0.
Proof.
First, let I(0) = I0 > 0 be a positive initial condition and suppose that ∃ t0 > 0
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Figure 3.16: Unbounded solution of (3.2.24) with a0 = 10, a1 = 0.01, a2 = 0.01,
a3 = 2.2, b1 = 0.001, b2 = 0.05, k = 5, τ = 10, p = 2, G(0) = 10000 and I(0) = 90.
such that I(t0) = 0. Then, at time t0, we have
I˙(t0) = b1G(t0 − τ)2.
If
1. G(t0 − τ) 6= 0, then I˙(t0) > 0 and we have a contradiction.
2. G(t0 − τ) = 0, then I˙ = 0 and so t0 is a high order zero. However, by noting
that the mth derivative of I is given by
I(m)(t0) = b1
m−1∑
j=0
m− 1
j
G(m−1−j)(t0 − τ)G(j)(t0 − τ)− b2I(m−1)(t0),
it can be seen that either
(a) ∃ j ∈ N such that
I(2j)(t0) = 0 & I
(2j+1)(t0) > 0,
which implies that t0 is a point of inflection, and hence we have a con-
tradiction, or
(b) I(j)(t0) = 0 ∀j, which also leads to a contradiction.
Hence, I(t) > 0 for all t. 
Due to the nature of this problem, unbounded solutions are not in our current scope
and therefore parameter values leading to such solutions will be not be investigated.
It is important to note that the introduction of an additional nonlinear term in
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the model, namely when a3 6= 0 and p > 1, can give rise to new dominant be-
haviour which may lead to singularities in the solutions. In particular, the presence
of movable poles can be assessed by performing a Painleve´-type analysis on each
dominant nonlinear truncation of the system. Here, we restrict ourselves to system
(3.2.24) without delays, for which arguments from Painleve´ analysis apply (Goriely
& Hyde 1998, Goriely & Hyde 2000).
Two such truncations of (3.2.24) can be distinguished
A. G˙ ∼ −a2GI B. G˙ ∼ −a3Ip
I˙ ∼ b1G2 I˙ ∼ b1G2
Looking for dominant terms of the form
G(t) ∼ α1(t− t0)q1 , I(t) ∼ α2(t− t0)q2 , (3.2.33)
one is led to the following solutions for each truncation
A. G ∼ 21/2
( −1
2a2b1
)1/2
(t− t0)−1 (3.2.34)
I ∼ 1
a2
(t− t0)−1 (3.2.35)
B. G ∼
(
(−1)pa3bp1(2p− 1)p+1
3p(p+ 1)
) 1
1−2p
(t− t0)
1+p
1−2p (3.2.36)
I ∼
(
−b1a
2
3(p+ 1)
−2(2p− 1)3
3
)
1
1−2p (t− t0)
3
1−2p (3.2.37)
The following conclusions can be drawn.
Truncation A. Since all parameters are assumed to be strictly positive, we see that
equation (3.2.34) does not give an expression with real coefficients. Therefore,
no open set of initial conditions lead to a movable pole (Goriely & Hyde 1998,
Goriely & Hyde 2000).
Truncation B. In order to have a pole, one needs to have that 2p > 1, which is
always satisfied here. This branch can therefore include resonances leading to
the presence of a movable pole (Goriely & Hyde 1998, Conte & Musette 2008,
Hone 2009).
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Therefore, from now on, we shall assume that parameters are selected such that I(t)
remains bounded, I(t) ≤ I+ <∞. We then have the following.
Proposition 4 Let I(t) be bounded from above, 0 ≤ I(t) ≤ I+ < ∞, with a0 >
a3I
p
+. Then G(t) is positive and bounded for all t > 0 if G(0) > 0.
Proof. From the first equation in system (3.2.24), it can be easily seen that
[G(s)e
∫ t
0 (a1+a2I(s))ds]t0 =
∫ t
0
e
∫ t
0 (a1+a2I(s))ds(a0 − a3I(t− kτ)p)ds
Hence G(t) is strictly positive for all t if a0 > a3I
p
+. Since we have that
G˙ ≤ a0 − a1G
when G(t) > 0 and a0 > a3I
p
+, using the arguments from Shi et al. (2017) (and
summarised in Subsection (3.2.1)) it can be easily seen that G(t) is bounded for all
t > 0. 
3.3 Periodic solutions in the linear system
In this section, we derive explicit conditions for the existence of sinusoidal solutions
for linear systems with two delays
x˙(t) = c1x(t) + c2y(t) + c3y(t− τ2), y˙(t) = c4x(t) + c5y(t) + c6x(t− τ1). (3.3.38)
The purpose of this derivation is twofold. On one hand, contrary to the case c4 = 0
where the solution of a transcendental equation is required, we show that conditions
can be formulated when c4 6= 0 by investigating the roots of a cubic polynomial.
On the other hand, in the context of model (3.1.1), the introduction of the co-
efficient c4 would correspond to a non-delayed glucose-dependent insulin secretion.
Hence our conditions provide a qualitative description of the effect of such an insulin
contribution.
We assume here that c3, c6 6= 0 to ensure the dependence upon the two delays is
preserved and postulate the form of the solution as
x(t) = A1 cos(ωt) + A2 sin(ωt), y(t) = B1 cos(ωt) +B2 sin(ωt). (3.3.39)
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Given that the system is linear, we impose that x(t) and y(t) are normalised such
that A21 + A
2
2 = 1, B
2
1 +B
2
2 = r
2, r > 0. Hence we set
A1 = cosφ, A2 = sinφ, B1 = r cos θ, B2 = r sin θ. (3.3.40)
Substituting (3.3.39) into (3.3.38), one obtains the following system
cos(τ1ω) = − 1
c6
[c4 + c5 cos z − rω sin z] , sin(τ1ω) = − r
c6
[c5 sin z + ω cos z] ,
cos(τ2ω) = − 1
c3r
[c2r + c1 cos z + ω sin z] , sin(τ2ω) =
1
c3r
[c1 sin z − ω cos z] ,
(3.3.41)
given that c3, c6 6= 0, where we introduced z = θ − φ. These lead to the following
conditions
ω2 + 2c2r (ω sin z + c1 cos z) + c
2
1 + r
2(c22 − c23) = 0, (3.3.42)
r2ω2 + 2c4r (c5 cos z − ω sin z) + r2c25 + c24 − c26 = 0. (3.3.43)
Here, we focus exclusively on the generic case where c2, c4, c1 + c5 6= 0. Conditions
when c2 = c4 = 0 for the local and global existence of periodic solutions have
been discussed, for example in Ruan & Wei (1999) using degree theory. We do not
make use of a rational transformation to bring the transcendental equation into a
polynomial problem (as done, for example in Sipahi & Olgac (2004) and Gu et al.
(2005)) or of geometric switching (see, e.g. Beretta & Kuang (2002) or An et al.
(2019)). In the generic case, one can solve (3.3.42) and (3.3.43) for sin z and cos z
and upon using that cos2 z + sin2 z = 1, obtain a cubic polynomial for ρ = ω2
b3ρ
3 + b2ρ
2 + b1ρ+ b0 = 0, (3.3.44)
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with
b0 =
(
c21c4c5 − c1c2c24 − c1c2c25r2 + c1c2c26 + c22c4c5r2 − c23c4c5r2
)2
,
b1 = c
4
1c
2
4 − 2c31c2c4c5r2 + 2c21c22c25r4 − 2c21c22c26r2 + 2c21c2c34 + 2c21c2c4c25r2
−2c21c2c4c26 − 2c21c23c24r2 + 2c21c24c25 − 2c1c32c4c5r4 − 8c1c22c24c5r2
+2c1c2c
2
3c4c5r
4 − 2c1c2c34c5 − 2c1c2c4c35r2 + 2c1c2c4c5c26 + c42c24r4
+2c32c
3
4r
2 + 2c32c4c
2
5r
4 − 2c32c4c26r2 − 2c22c23c24r4 + c22c44 − 2c22c24c26 + c22c45r4
−2c22c25c26r2 + c22c46 − 2c2c23c34r2 − 2c2c23c4c25r4 + 2c2c23c4c26r2
+c43c
2
4r
4 − 2c23c24c25r2,
b2 = c
2
1c
2
2r
4 + 2c21c2c4r
2 + 2c21c
2
4 − 2c1c2c4c5r2 + 2c32c4r4
+4c22c
2
4r
2 + 2c22c
2
5r
4 − 2c22c26r2 − 2c2c23c4r4 + 2c2,
b3 =
(
c2r
2 + c4
)2
.
The polynomial (3.3.44) always possesses at least one real root for ρ. We now
investigate conditions which ensure that it possesses at least one positive root and
discard the case b0 = 0, which would lead to a constant solution. Assuming a
factorisation of the form
b3(ρ− ρ1)(ρ− ρ2)(ρ− ρ3)
= b3
[
ρ3 − (ρ1 + ρ2 + ρ3)ρ2 + (ρ1ρ2 + ρ1ρ2 + ρ2ρ3)ρ− ρ1ρ2ρ3
]
,
the fact that b0 and b3 are positive implies that the product of roots ρ1ρ2ρ3 is
negative. Hence, the polynomial either has 1 or 3 negative roots. Moreover, if two
roots are complex, say ρ3 = ρ2, then
ρ1ρ2ρ3 = ρ1ρ2ρ¯2 = ρ1|ρ2|2 < 0⇒ ρ1 < 0
and the polynomial has no positive root. Hence, for the polynomial (3.3.44) to
have at least one positive root, its three roots must be real, or equivalently the
discriminant of (3.3.44) must be positive. As a consequence, the only choice is to
have 1 negative root and 2 positive ones. According to Descartes’ rule of signs, the
series of coefficients of polynomial (3.3.44) must exhibit exactly two sign changes,
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while the series obtained upon setting x→ −x must have exactly one sign change.
This leads to the following proposition.
Proposition 5 In the generic case c2, c4, c1 + c5 6= 0, system (3.3.38) possesses at
least one sinusoidal solution if the discriminant of (3.3.44),
∆ = 18b0b1b2b3 − 4b32b0 + b21b22 − 4b3b31 − 27b20b23
is positive and either i) b2 < 0 or ii) b2 > 0 and b1 < 0 or iii) b1 = 0 or b2 = 0 holds.
Moreover, values of z can be obtained directly by eliminating ω from (3.3.42) and
(3.3.43),
8c2c4(c1 + c5)r
3
(
c2r
2 + c4
)
η3
−4r2
[
c2r
4
(
c21c2 − c22c4 − c2c25 + c23c4
)
+r2
(
c22c
2
6 + c
2
3c
2
4 − c21c2c4 − 2c1c2c4c5 − 2c22c24 − c2c4c25
)
−c4
(
c21c4 + c2c
2
4 − c2c26 − c4c25
) ]
η2
−4r
[
c1c2(c
2
2 − c23)r6 +
(
c31c2 + 2c1c
2
2c4 − c1c2c25 + c22c4c5 + c23c4c5
)
r4(
c4c
3
5 − c21c4c5 + c1c2c24 + c1c2c26 + 2c2c24c5
)
r2 + c4c5(c
2
4 − c26)
]
η
−
[
(c22 − c23)2r8 + 2
(
c21c
2
2 − c21c23 + 2c32c4 + c22c25 − 2c2c23c4 + c23c25
)
r6
(c41 + 4c
2
1c2c4 − 2c21c25 + 6c22c24 − 2c22c26 + 4c2c4c25 − 2c23c24 − 2c23c26 + c45)r4
+2
(
c21c
2
4 + c
2
1c
2
6 + 2c2c
3
4 − 2c2c4c26 + c24c25 − c25c26
)
r2 + (c24 − c26)2
]
= 0,
(3.3.45)
where η = cos z. Using equations (3.3.42) and (3.3.43) one can then obtain the
points in the positive (τ1, τ2) domain where sinusoidal solutions of the form (3.3.39)
exist. We now give an example using as starting point the linearisation of system
(3.1.1) in which we introduce the coefficient c4.
Example 1 Physiological parameters for system (3.1.1) in the non-diabetic case
α = β = γ = 1 were obtained in Huard et al. (2015). Note that in that case c4 = 0
and here we assume that c4 is sufficiently small and represents a first-order approx-
imation of an instantaneous glucose-dependent insulin release. The corresponding
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values are given by
c1 = −0.010, c2 = −0.855, c3 = −2.457, c5 = −0.06, c6 = 0.001. (3.3.46)
Following the procedure just highlighted, it can be seen (Fig. 3.17) that for each
value of −1 ≤ c4 ≤ 1, there exists a small range on r for which the conditions of
Proposition 5 are satisfied. For example, for c1 = 0.00001, the range of 0.0145619 ≤
r ≤ 0.0170074 is determined numerically with corresponding ω’s within [0.0253264,
0.0471886]. For each value of r, values of ω and z are obtained from (3.3.44) and
(3.3.45). For each trio (r, ω, z), equations (3.3.41) are then used to obtain the
resulting values for τ1 and τ2. Because of the periodicity of these equations, we
report here only the minimal positive values of the delays.
Figure 3.17: Values of r which satisfy the conditions of Proposition 5 for c4 ∈ [−1, 1].
Increasing c4 has a crucial effect of the production of sinusoidal solutions (Fig.
3.18). The lower branch of the graph for c4 = 0.00001 gives an approximation to
the transcendental curve of Hopf bifurcations which was presented in Fig. 3.4. The
graph in Fig. 3.18 shows that this curve is part of a closed loop in this space. For
comparison, increasing c4 and repeating the analysis shows that it deforms this loop
by shrinking it progressively, here represented for c4 = 0.1. We observe numerically
that values of c4 larger than around 39.02 cannot lead to an oscillatory solution.
However, in the context of glucose-insulin regulation, it is reasonable to expect that
a value above the delayed insulin production or the degradation rate will break the
ability of the system to generate oscillations.
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Figure 3.18: Existence of oscillatory solutions in the (τ1, τ2) domain for c4 = 0.00001
(left) and c4 = 0.1 (right). Given the periodicity of equations (3.3.41), only the
curves which provide the minimal values for τ2 are reported.
Chapter 4
Strategies for stabilising glucose
levels and restoring oscillations
In this chapter, we first look at a variety of different treatment strategies for both
T1DM and T2DM. While many of the strategies discussed are used currently used
in practice, some are in a more theoretical stage. We then look at using some of the
strategies as a way of: (1) maintaining a physiological acceptable blood glucose level;
and (2) restoring an accurate oscillatory regime. Finally, we look to combine two of
the strategies to investigate whether a combined approach is better at enabling the
two objectives.
4.1 Clinical and Theoretical Treatments for Dia-
betes
4.1.1 Background
Research into the treatment and understanding of diabetes has made significant
progress since the hormone insulin was first coined by Sir Edward Albert Sharpey-
Schafer in 1910 (American Diabetes Association 2015). The advances made (along
with an improvement of patient care) have been shown to have reduced the incidence
of diabetic complications significantly over the last 20 years (American Diabetes
Association 2015). However, there are still many aspects of the illness that remain
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a mystery.
4.1.2 Insulin Therapy
In current practice, daily insulin doses are used as the main treatment for all Type
1 diabetics, as well as for some with T2DM (Centers for Disease Control and Pre-
vention et al. 2011) (although the use of insulin therapy in the initial treatment
for T2DM is debated (Pories & Dohm 2012)). These insulin doses can be taken by
injection or through an insulin pump (Centers for Disease Control and Prevention
et al. 2011).
4.1.3 Metformin
Metformin is a Biguanidine drug which is used in the treatment of T2DM (Centers
for Disease Control and Prevention et al. 2011). It has been shown to: lower the
fasting plasma glucose concentration (Hundal et al. 2000); inhibit hepatic glucose
production (Hundal et al. 2000); and improve insulin resistance (Giannarelli et al.
2003).
4.1.4 Insulin Degradation
In circulation, insulin is known to have a short half-life. This is likely due to the high
efficiency of its clearance mechanisms, for example degradation by IDE (Tang 2016).
Defects in IDE have long been linked to the development of serious conditions, such
as T2DM and Alzheimer’s disease (Tang 2016). Indeed, Farris et al. (2003) showed
that increased insulin levels resulting from significantly reduced insulin clearance is
sufficient enough to lead to glucose intolerance. While the potential role of hyper-
insulinemia in the aggravation of insulin resistance is a subject of debate (Pories &
Dohm 2012), it appears of crucial importance to identify mechanisms which keep
both glucose and insulin levels within a physiologically acceptable range. One such
mechanism could be insulin clearance. Indeed, over the years there has been much
speculation that reducing insulin degradation may be used to treat T2DM (Mirsky
& Broh-Kahn 1949, Duckworth, Bennett & Hamel 1998) and in Maianti et al. (2014)
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it was shown that acute inhibition of IDE in mice lead to substantially improved
glucose tolerance.
However, there are still many unanswered questions regarding the use of IDE
inhibitors in humans (Tang 2016), and a lot of work still needs to be done to see if
they can be used prolonged periods of time (Hogan et al. 2016). Nevertheless, their
use represents an encouraging avenue for clinical treatment (Tang 2016).
4.2 Strategies
We now investigate strategies allowing the stabilisation of the basal glucose level
and/or the restoration of oscillations using the insulin degradation or insulin infusion
as a bifurcation parameter. As stated in Section 3.1, di(α, β) can be viewed as
a combination of natural and artificial processes which regulate the clearance of
insulin. Indeed, under the assumption that the insulin degradation rate is adjusted in
a continuous way, proportionally to the insulin levels, this effect can be incorporated
into di(α, β). Our analysis for the stabilisation processes makes use of equations
(3.1.3) and (3.1.4) for the steady state (G¯, I¯), as given in Section 3.
In the optimal non-diabetic case α = β = γ = 1, the current choice of parameters
from Tables 3.1 and 3.2 gives a value of G¯ ≈ 97.87 mg/dl, which we use as the
reference value.
The effect of this stabilisation mechanism on the generation of an oscillatory
regime is also investigated as follows. It is known that for all values of A, B, C,
D (as defined in (3.1.2)), di(α, β), and any fixed τ1, there exists a τ
∗
2 (τ1) such that
the characteristic equation (3.1.9) undergoes a supercritical Hopf bifurcation in the
(τ1, τ2) space (Li & Kuang 2007). If we then suppose that an individual has fixed
secretion time delays (here we use τ1 = 6 and τ2 = 36), then for a fixed pair (α,β)
one can compute the point of Hopf bifurcation τ ∗2 (6) using formulas (3.1.13) and
(3.1.14). Since every τ2 > τ
∗
2 (6) will lead to an oscillatory regime (see Fig. 3.4),
this provides an easy way to verify whether the pair (α,β) is oscillatory, and hence
allows to decide whether specific values of α and β for a given individual (with fixed
τ1 and τ2) lead to an oscillatory regime.
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4.2.1 Using insulin injections to stabilise the glucose level
We assume here that a continuous insulin infusion may allow the stabilisation of the
basal glucose level. Indeed since the steady state (G¯, I¯) satisfies equations (3.1.3)
and (3.1.4), it is easily computed that in order to keep G¯ constant, for fixed Gin, α, β
and γ, one can solve equation (3.1.3) numerically to obtain I¯ while equation (3.1.4)
gives
Iin = di(α, β)I¯ − αf1(G¯). (4.2.1)
Using the algorithm detailed above, we determine whether each (α,β), with Iin as
defined by (4.2.1) and di = 0.06, leads to an oscillatory regime. The result is shown
in Fig. 4.1. For physiological accuracy, only values of (α,β) where Iin > 0 were
considered. It can be seen that insulin injections are indeed able to stabilise the
basal glucose level for a vast range of diabetic states. However, in the case when
γ = 1, oscillations are only present/restored for a small range of α and β. This
range was further reduced when γ was decreased.
Figure 4.1: Oscillatory region (in red) in the α, β domain for di = 0.06 with Iin as
defined by (4.2.1) with γ = 0.7 (left) and γ = 1 (right). The blue region represents
values of (α, β) for which G¯ remains constant at 97.87, but the system is stable. The
white region represents values of (α, β) where the resulting value of Iin is negative.
As seen from Fig. 4.2, changing τ1 and τ2, which is equivalent to looking at
different individuals, has very little effect on the range for which oscillations can
be restored using a constant insulin infusion. Indeed, when Gin = 1.35, oscillations
cannot be restored when β < 0.9 irrespective of the value of the delays chosen.
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Interestingly, the oscillatory region also remains relatively unchanged for varying
delays when Gin = 0.54. However, unlike when Gin = 1.35, the oscillations can be
restored for a larger range of diabetic states when Gin = 0.54 (Fig. 4.3). Even so,
there still exists a critical value of β such that if β < βcr then oscillations cannot be
restored.
4.2.2 Reducing hepatic glucose production to stabilise the
glucose level
Inhibiting hepatic glucose production can also be seen as a mechanism for reducing
glucose levels, as employed by several medications occurring in the treatment of
T2DM (Hundal et al. 2000). Let us consider a situation where insulin resistance is
present, β < 1, and investigate under which circumstances the reduction of hepatic
glucose allows to keep the value of G¯ constant. Assuming di and Iin are fixed, (3.1.3)
and (3.1.4) can be rearranged to obtain the stabilising value of γ,
γ =
Gin − f2(G¯)− βf3(G¯)f4( Iin+αf1(G¯))di )
f5(
Iin+αf1(G¯))
di
)
. (4.2.2)
It can be seen in equation (4.2.2) that there is a linear relationship between β
and γ in compensating insulin resistance by reducing hepatic glucose production.
Applying the algorithm described previously, one can assess whether the resulting
choice leads to an oscillatory regime. The result is illustrated in Fig. 4.4. Indeed,
it is seen that there is a small region of (α, β) for which G¯ is kept constant and
oscillations occur. On the other hand, for the current choice of parameters, neither
the restoration of oscillations or the stabilisation of G¯ is possible when both (α, β)
< 0.8. Therefore the reduction of the hepatic glucose production on its own may
not be an effective strategy for the restoration of oscillations in the diabetic state.
However, as mentioned in Subsection 4.1.3, drugs like Metformin lower both the
hepatic glucose production and insulin resistance (Hundal et al. 2000). Therefore,
physiologically, this strategy may be more effective than Fig. 4.4 suggests.
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(a) τ1 = 6, τ2 = 36 (b) τ1 = 6, τ2 = 30
(c) τ1 = 5, τ2 = 36 (d) τ1 = 5, τ2 = 30
(e) τ1 = 8, τ2 = 36 (f) τ1 = 8, τ2 = 30
Figure 4.2: Oscillatory regions in the α, β domain for various values of τ1 and τ2.
The red, blue and white regions are as defined in Fig. 4.1.
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(a) τ1 = 6, τ2 = 36 (b) τ1 = 6, τ2 = 30
(c) τ1 = 5, τ2 = 36 (d) τ1 = 5, τ2 = 30
(e) τ1 = 8, τ2 = 36 (f) τ1 = 8, τ2 = 30
Figure 4.3: Oscillatory regions in the α, β domain for various values of τ1 and τ2
with Gin = 0.54 mg/dl min. The red, blue and white regions are as defined in Fig.
4.1, although it is noted that G¯ is now stabilised to 89 which is the value of the
steady state when α = β = γ = 1 for Gin = 0.54.
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Figure 4.4: Value of γ, as defined by (4.2.2), that enables the stabilisation of G¯ =
97.87 mg/dl for each β with α = 1 (left) and the resulting oscillatory region in the
α, β domain with di = 0.06, Iin = 0 (right, red). The blue region represents values
of (α,β) such that G¯ = 97.87 but oscillations do not occur. Finally, the white region
corresponds to negative values of γ, which are physiologically impossible.
4.2.3 Altering insulin degradation to stabilise the glucose
level
As mentioned in Section 4.2.1, since the steady state (G¯, I¯) satisfies equations (3.1.3)
and (3.1.4), it can be easily computed that
Gin − f2(G¯)− βf3(G¯)f4(I¯) + γf5(I¯) = 0, (4.2.3)
I¯ =
Iin + αf1(G¯)
di(α, β)
. (4.2.4)
Using (4.2.3) and (4.2.4), with fixed α, we can determine the function di(α, β)
which stabilises the glucose basal level to 97.87 mg/dl and the resulting insulin basal
level, I¯. These can be seen in Fig. 4.5.
The graphs clearly show that in the case of moderate insulin resistance (β ∈
[0.6, 1]), it is possible to keep both the glucose and insulin basal levels relatively
unchanged by altering the insulin clearance rate.
It is readily seen that this strategy can be applied in the case of limited insulin
resistance.
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Figure 4.5: Clearance rate which allows to stabilise G¯ = 97.87mg/dl and the result-
ing I¯ when di(1, 1) = 0.06 and Iin = 0.
Figure 4.6: Oscillatory region (in red) in the α, β domain for di = 0.06 (left) and
di(α, β) defined by (4.2.3), with Iin = 0.
4.2.4 Reintroducing oscillations
This strategy focuses primarily on the reintroduction of an oscillatory regime. To
this end, we use di as a bifurcation parameter to assess whether altering insulin
clearance may be used for this purpose. However, a Hopf bifurcation has only been
shown to occur in the (τ1, τ2) space, and so we use the algorithm outlined previously
in order to determine whether the system oscillates for a given (α, β, di), and hence
obtain the oscillatory region in the (α, β, di) space (shown in Fig. 4.7) . We also
verify that the resulting fasting glucose levels fall within an acceptable physiological
range. It can be seen from Fig. 4.7 that changing di is considerably more effective for
restoring oscillations for large variations of α than β. Indeed, for values of β < 0.9,
di cannot be used to restore the oscillatory regime of the system and keep the fasting
glucose levels within an acceptable range.
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Figure 4.7: Oscillating regions in the α, β, di domain. The solid sections represent
the values of di for which both oscillations occur, and the fasting glucose levels lay
within an acceptable range (70-109 mg/dl).
4.2.5 Combining strategies
The final strategy combines the use of both γ and di to assess whether a larger range
of diabetic states can be successfully recalibrated. We proceed as follows. For fixed
values of α, β and delays, we look at whether any value in the ranges di ∈ [0.01, 0.3]
and γ ∈ (0, 1] leads to an oscillatory solution with acceptable fasting glucose values.
As seen in Fig 4.8, this combination does extend the range of (α, β) values which
can be successfully recalibrated. In particular, even in cases where insulin secretion
is relatively low, the retuning of insulin degradation and hepatic production enables
the restoration of an oscillatory regime.
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Figure 4.8: Values of α and β for which oscillations can be restored with a healthy
fasting basal level using a combined strategy.
Chapter 5
Amplitude and frequency variation
This chapter provides an analysis of the variation of amplitude and frequency in the
simplified nonlinear model with respect to the model parameters. This is achieved
through the perturbation of periodic solutions in a neighbourhood of the critical
manifold. This technique is usually referred to as the Poincare´-Lindstedt (P-L)
expansion (Verhulst 2006, pp. 122–127).
In Section 5.1.1 we first consider the case when hepatic glucose production is
assumed to be constant (see model (5.1.1)), in which case the small bifurcation
parameter  > 0 represents the distance from the critical τ0. Then in Section
5.1.2 we extend our considerations to the two delay case by assuming that the
second delay is a constant multiple of the first one, thus defining a fan of expansion
lines in the space of delays (see model (5.1.20)). Finally, the effect of the model
parameters on the expressions for the amplitude and period are analysed in Section
5.2, with Subsections 5.2.1 and 5.2.2 focusing on the expressions for models (5.1.1)
and (5.1.20), respectively.
5.1 Hopf-bifurcation formulae
The P-L technique is a method for finding approximate expressions for periodic so-
lutions of nonlinear systems through the removal of secular terms. It was extended
to differential equations with explicit delay by Casal & Freedman (1980) and has
been applied in a limited number of studies to highlight the contribution of parame-
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ters to the amplitude of oscillations. For example, Verdugo & Rand (2008) used the
P-L technique to predict the amplitude and frequency of a two compartment DDE
model of gene expression with one delay, while Brandt, Pelster & Wessel (2006) used
it to calculate the frequency of a two compartment DDE model, representing two
coupled Hopfield neurons, with two equal delays. The P-L method has also served
as a basis for developing a Floquet theory of time periodic states (Simmendinger,
Wunderlin & Pelster 1999).
Throughout this section, it is assumed that the frequency of the periodic solution
of the linearised system, ω0, does not satisfy an equation of order lower than the
characteristic equation.
5.1.1 Constant hepatic glucose production
Recall from Section 3.2.1 that the simplified model with a constant hepatic glucose
production term, with n = 2, is given by
G˙(t) = Gin − a1G(t)− a2G(t)I(t) + C,
I˙(t) = b1G(t− τ1)2 − b2I(t), τ = τ1.
(5.1.1)
Defining
X(t) = X = G(t)− G¯, Y (t) = Y = I(t)− I¯ ,
as deviations from the positive equilibrium, and substituting into (5.1.1) leads to
X˙ = −a1X − a2
(
XY + I¯X + G¯Y
)
, (5.1.2)
Y˙ = b1X
2
τ + 2b1G¯Xτ − b2Y.
Eliminating Y in (5.1.2) allows us to write the following second-order DDE for X
(
G¯+X
)
X¨ − X˙2 + (a0 + b2(G¯+X)) X˙
+
(
G¯+X
) ((
a1 + a2I¯
)
b2X + a2b1
(
G¯+X
)
Xτ
(
2G¯+Xτ
))
= 0. (5.1.3)
We now introduce the bifurcation parameter , which is defined as the distance from
the critical delay τ0 as follows
 =
√
τ − τ0. (5.1.4)
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The state variable X is then scaled as
X(t) = u(s), (5.1.5)
where
s = Ω () t (5.1.6)
corresponds to a new time variable ensuring that u(s) has a period of 2pi. Here, Ω
is also assumed to have an -expansion
Ω = ω0 + ω1 + 
2ω2 + 
3ω3 + ..., (5.1.7)
where ω0 is the frequency associated to the critical value τ0. Finally, we expand the
delayed term uτ
u(s− Ωτ) = u(s− τ0ω0)− τ0ω1u˙(s− τ0ω0) (5.1.8)
+ 2
(
1
2
τ 20ω
2
1u¨(s− τ0ω0)− u˙(s− τ0ω0)(ω0 + τ0ω2)
)
+O(3),
along with u and its derivatives
u(s) = u0(s) + u1(s) + 
2u2(s) + ... (5.1.9)
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Substituting into (5.1.3) and collecting terms (up to and including O(2)) gives
ω20u¨0 + u˙0ω0(a2I¯ + a1 + b2) + b2u0(a2I¯ + a1) + 2a2b1G¯
2u0τ = 0, (5.1.10)
ω20u¨1 + u˙1ω0(a2I¯ + a1 + b2) + b2u1(a2I¯ + a1) + 2a2b1G¯
2u1τ
+ G¯−1(u0(4a2b1G¯2u0τ + ω0(b2u˙0 + ω0u¨0)− 2a2b1G¯3ω1τ0u˙0τ ) + a2b1G¯2u20τ
+ b2u
2
0(a2I¯ + a1) + a2G¯I¯ω1u˙0 + a1G¯ω1u˙0 + b2G¯ω1u˙0 + 2G¯ω1ω0u¨0 − ω20u˙20) = 0,
(5.1.11)
ω20u¨2 + u˙2ω0(a2I¯ + a1 + b2) + b2u2(a2I¯ + a1) + 2a2b1G¯
2u2τ
+ G¯−1(a2b1G¯3ω21τ
2
0 u¨0τ − 2a2b1G¯3ω2τ0u˙0τ − 2a2b1G¯3ω1τ0u˙1τ − 2a2b1G¯3ω0u˙0τ
+ u0(4a2b1G¯
2u1τ − 4a2b1G¯2ω1τ0u˙0τ + 2a2b1G¯u20τ + 2b2u1(a2I¯ + a1) + b2ω1u˙0
+ b2u˙1ω0 + 2ω1ω0u¨0 + ω
2
0u¨1) + 2a2b1G¯
2u0τ (u1τ − ω1τ0u˙0τ + 2u1) + 2a2b1G¯u20u0τ
+ a2G¯I¯ω2u˙0 + a2G¯I¯ω1u˙1 + a1G¯ω2u˙0 + a1G¯ω1u˙1 + b2G¯ω2u˙0 + b2G¯ω1u˙1 + b2u1u˙0ω0
+ 2G¯ω2ω0u¨0 + 2G¯ω1ω0u¨1 + G¯ω
2
1u¨0 − 2ω1u˙20ω0 + u1ω20u¨0 − 2u˙0u˙1ω20) = 0, (5.1.12)
with uiτ = ui(s− τ0ω0). The seed solution is chosen as
u0(s) = A0 cos(s) +B0 sin(s) (5.1.13)
and since (5.1.10) is linear, A0 and B0 are arbitrary. Without loss of generality, we
impose the initial condition u0(
pi
2
) = 0, giving
u0(s) = A0 cos(s) (5.1.14)
where, following (5.1.5), A0 is related to the amplitude of x (denoted by A¯) by
A¯ = A0. Choosing
u1(s) = A1 sin(s) +B1 cos(s) + C1 sin(2s) +D1 cos(2s) + E1 (5.1.15)
and substituting into (5.1.11) and comparing coefficients of the cos(s) and sin(s)
terms shows that: (1) A1, B1 are arbitrary (2) ω1 = 0. From comparison of the
cos(2s) and sin(2s) coefficients, it can be shown that
C1 =
A20F
G
, D1 =
A20H
K
, E1 =
A20(2a1b2 − a2(2b1G¯2 − 2b2I¯))
4G¯(a2(2b1G¯2 + b2I¯) + a1b2)
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where F , G, H and K are some functions of a1, a2, b1, b2, G¯, I¯, ω0. Due to their
length, they are not reproduced here. By substituting
u2(s) =A2 sin(s) +B2 cos(s) + C2 sin(2s) +D2 cos(2s)
+ E2 sin(3s) + F2 cos(3s) +G2 (5.1.16)
along with (5.1.15) and (5.1.13) into (5.1.12), and comparing the coefficients of the
cos(s) and sin(s) terms, the dominant term for the amplitude, A¯, of the limit cycle
is expressible as
A¯2 =
8G¯2ρ
(
2a2b1G¯
3 + a0b2
) (
a20 + G¯
2 (b22 + 2ρ)
)
p1∑7
m=0(p2,m + τ0p3,m)a
m
0
2, (5.1.17)
while the dominant term of the amplitude of the insulin oscillations, B¯, and the
second-order term for frequency correction, ω2, are given by
B¯ =
A¯
a2G¯
√
ρ+
a20
G¯2
, ω2 =
−√ρ∑7m=0 p3,mam0∑7
m=0(p2,m + τ0p3,m)a
m
0
. (5.1.18)
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Here, we introduced the following definitions
ρ =ω20,
p1 = 4a2b1G¯
3
(
b32
(
a30 + 3a0G¯
2ρ
)
+ 3a0b2ρ
(
a20 + 3G¯
2ρ
)− 4G¯3ρ3)+ b2ρ (a20 + G¯2ρ)2
+ 4a22b
2
1G¯
6b4ρ
(
a20 + 4G¯
2ρ
)
,
p2,0 = 16a2b1b2G¯
9ρ2
(
8a22b
2
1G¯
4b4ρ − 2a2b1G¯2
(
5b22ρ+ b
4
2 + 12ρ
2
)
+ ρb2ρ
)
,
p2,1 = 2G¯
6ρ(64a32b
3
1G¯
6(2b22 + 3ρ)b4ρ − 4a22b21G¯4ρ(59b22ρ− 5b42 + 92ρ2)
+ a2b1G¯
2ρ(59b22ρ
2 + 12b42ρ+ 7b
6
2 + 22ρ
3)− 2b22ρ2b2ρ),
p2,2 = b2G¯
5ρ(320a32b
3
1G¯
6b4ρ + 4a
2
2b
2
1G¯
4(97b22ρ+ 31b
4
2 + 6ρ
2)
+ 2a2b1G¯
2ρ(b42 + 39ρ
2)− ρ(3b22 + 2ρ)b2ρ),
p2,3 = G¯
4(16a32b
3
1G¯
6(3b22 + 2ρ)b4ρ + 4a
2
2b
2
1G¯
4ρ(85b22ρ+ 43b
4
2 − 38ρ2)
+ 2a2b1G¯
2ρ(28b22ρ
2 − 59b42ρ− 7b62 + 44ρ3)− 11b22ρ2b2ρ),
p2,4 = 2b2G¯
3(24a32b
3
1G¯
6b4ρ + 2a
2
2b
2
1G¯
4(21b22ρ+ 9b
4
2 + 16ρ
2)
− a2b1b22G¯2ρ(7b22 + 59ρ)− ρ(3b22 + 2ρ)b2ρ),
p2,5 = 2G¯
2(6a22b
2
1G¯
4(5b22ρ+ 3b
4
2 − 6ρ2) + a2b1G¯2ρ(11b22ρ− 15b42 + 22ρ2)− 5b22ρb2ρ),
p2,6 = − b2G¯(6a2b1G¯2ρ(5b22 + ρ) + (3b22 + 2ρ)b2ρ),
p2,7 = − 3b22b2ρ,
p3,0 = 16a2b1G¯
9ρ2bρ(8a
2
2b
2
1G¯
4b4ρ − 12a2b1G¯2ρ2 + ρb2ρ),
p3,1 = − 4b2G¯6ρ2bρ(2a22b21G¯4(ρ− 5b22)− 24a2b1G¯2ρ2 + ρb2ρ),
p3,2 = 2a2b1G¯
7ρbρ(160a
2
2b
2
1G¯
4b4ρ − 156a2b1G¯2ρ2 + ρ(−28b22ρ+ b42 + 31ρ2)),
p3,3 = b2G¯
4ρbρ(4a
2
2b
2
1G¯
4(43b22 + 85ρ) + 132a2b1G¯
2ρ2 − 11ρb2ρ),
p3,4 = 2a2b1G¯
5bρ(24a
2
2b
2
1G¯
4b4ρ + ρ(36a2b1G¯
2ρ− 59b22ρ− 7b42 + 38ρ2)),
p3,5 = 2b2G¯
2bρ(6a
2
2b
2
1G¯
4(3b22 + 5ρ) + 18a2b1G¯
2ρ2 − 5ρb2ρ),
p3,6 = 30a2b1G¯
3ρ(ρ− b22)bρ,
p3,7 = − 3b2b3ρ,
with bρ = b
2
2 + ρ and b4ρ = b
2
2 + 4ρ. Finally, we note that the period of the limit
cycle, T , is given by
T =
2pi
ω0 + 2ω2
. (5.1.19)
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Simulations making use of expressions (5.1.17), (5.1.18), and (5.1.19) are presented
in Section 5.2.1.
5.1.2 Linear hepatic glucose production
We now turn to study the effect of a non-constant hepatic glucose production, and
hence a second delay, on the limit cycles (see model (3.2.24)). As mentioned in the
introduction to this section, the P-L method has indeed been used in a limited num-
ber of studies to investigate the effect of model parameters on the amplitude of the
resulting oscillatory solutions. For example, in Brandt et al. (2006) a coupled first-
order DDE model describing a two-neuron system with delay was explored. While
the system had two separate delays, these were combined giving a characteristic
equation of the form
λ2 + A1λ+ A2 + A3e
−λτ = 0, τ = τ1 + τ2,
with A1, A2 constant and A3 a function of the model parameters. In contrast,
the characteristic equation of model (3.2.24), given by (3.2.26), contains a second
exponential term which leads to additional challenges in finding points of bifurcation,
as discussed in Section 3.2.1. For conciseness, we will assume that p = 1 in model
(3.2.24) for the following P-L calculation, although the technique can be applied to
higher orders. The resulting model is hence given by
G˙(t) = a0 − a1G(t)− a2G(t)I(t)− a3I(t− kτ), (5.1.20)
I˙(t) = b1G(t− τ)2 − b2I(t),
where the dimensionless parameter k is used to represent the commensurateness of
the time delays. As with the calculation in the previous section, we state that
X = G(t)− G¯, Y = I(t)− I¯ .
Let (ω0, τ0) be a critical pair obtained using the algorithm described in Section 3.2.1.
Then by introducing  =
√
τ − τ0, as in (5.1.4), we can scale the variables X and Y
as
X(t) = u(s), Y (t) = v(s), (5.1.21)
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where s is the scaled time variable as defined in (5.1.6). The expansions for v(s)
and v(s− kωτ) are
v(s− Ωτ) =v(s− kτ0ω0)− kτ0ω1v˙(s− kτ0ω0) (5.1.22)
+
1
2
k2(τ0(kτ0ω
2
1 v¨(s− kτ0ω0)− 2ω2v˙(s− kτ0ω0))
− 2ω0v˙(s− kτ0ω0)) +O(3),
v(s) =v0(s) + v1(s) + 
2u2(s) + ... (5.1.23)
Following the steps outlined in (5.1.6) - (5.1.9), substituting into (5.1.20) and col-
lecting terms (up to and including O(3)) gives
dum
ds
= −(a1 + a2I¯)
ω0
um − a2G¯
ω0
vm − a3
ω0
vmτ + gm, (5.1.24)
dvm
ds
= − b2
ω0
vm +
2b1G¯
ω0
umτ + hm, (5.1.25)
with m = 0, 1, 2, umτ = um(s− τ0ω0), vmτ = vm(s− kτ0ω0) and where the inhomo-
geneous terms gm and hm are related to the solutions of previous orders. Here we
have g0 = 0, h0 = 0, and
g1 =− a2u0v0 + a3kω1τ0 ˙v0τ − ω1u˙0, (5.1.26)
h1 =b1u0τ
2 − 2b1G¯ω1τ0 ˙u0τ − ω1v˙0, (5.1.27)
g2 =− a2u1v0 − a2u0v1 − 1
2
a3k
2ω21τ
2
0 v¨0τ + a3kω1τ0 ˙v1τ + a3kω0 ˙v0τ
+ a3kω2τ0 ˙v0τ − a3v2τ + ω1u˙1 − ω2u˙0, (5.1.28)
h2 =2b1u0τ (u1τ − ω1τ0 ˙u0τ )− 2b1G¯ω1τ0 ˙u1τ − 2b1G¯ω0 ˙u0τ − 2b1G¯ω2τ0 ˙u0τ
+ b1G¯ω
2
1τ
2
0 u¨0τ − ω1v˙1 − ω2v˙0. (5.1.29)
By imposing the initial conditions u0(0) = C0, v0(0) = C0R1 on the solutions of
(5.1.24) and (5.1.25), with m = 0 we find that
u0(s) = C0 cos(s), (5.1.30)
v0(s) = C0R1 cos(s) + C0R2 sin(s), (5.1.31)
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where
R1 =
1
Q
(−ω0(a1 + a2I¯ − b2) + a1b2 − 2a2b1G¯2 sin(τ0ω0) + 2a2b1G¯2 cos(τ0ω0) + a2b2I¯
+ 2a3b1G¯ sin((k − 1)τ0ω0) + 2a3b1G¯ cos((k + 1)τ0ω0)− ω20),
R2 =
1
Q
(ω0(a1 + a2I¯ + b2) + a1b2 − 2a2b1G¯2 sin(τ0ω0) + 2a2b1G¯2 cos(τ0ω0) + a2b2I¯
− 2a3b1G¯ sin((k + 1)τ0ω0) + 2a3b1G¯ cos((k − 1)τ0ω0) + ω20),
Q = 2(ω0(a2G¯+ a3 cos(kτ0ω0)) + a3b2 sin(kτ0ω0)).
We note that C0 is related to the amplitude of X(t) (denoted by C¯) by C¯ = C0,
and that the amplitude of Y (t) (denoted by D¯) is given by
D¯ = C¯
√
R21 +R
2
2. (5.1.32)
As we necessitate that the solutions um and vm are periodic in s with period 2pi, we
must find conditions such that the inhomogeneities do not contain secular terms.
Hence, we proceed as in Brandt et al. (2006) and expand um, vm, gm and hm as
Fourier series to getum(s)
vm(s)
 = ∞∑
κ=0
a(m)1,κ
a
(m)
2,κ
 cos(κs) +
b(m)1,κ
b
(m)
2,κ
 sin(κs)
 , (5.1.33)
gm(s)
hm(s)
 = ∞∑
κ=0
α(m)1,κ
α
(m)
2,κ
 cos(κs) +
β(m)1,κ
β
(m)
2,κ
 sin(κs)
 . (5.1.34)
Substituting (5.1.33) and (5.1.34) into (5.1.24) and (5.1.25), it can be seen that
the coefficients, α
(m)
j,1 , β
(m)
j,1 (with j = 1, 2), in the inhomogeneities gm and hm must
satisfy the following conditions
−a2α(m)2,1 G¯+ α(m)1,1 b2 − α(m)2,1 a3 cos(τ0ω0) + a3β(m)2,1 sin(τ0ω0) + β(m)1,1 ω0 = 0, (5.1.35)
−α(m)1,1 ω0 − a2β(m)2,1 G¯+ b2β(m)1,1 − α(m)2,1 a3 sin(τ0ω0)− a3β(m)2,1 cos(τ0ω0) = 0. (5.1.36)
For further details of the derivation of these conditions, the reader is referred to the
next subsection.
When κ = 1, the coefficients of the inhomogeneities g1 and h1 are
α
(1)
1,1 =
kC0τ0ω1v1
v5ω0
, β
(1)
1,1 =
C0ω1(kτ0v2 − 2v1)
v5ω0
, α
(1)
2,1 =
C0ω1v3
v5
, β
(1)
2,1 =
C0ω1v4
v5
,
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where
v1 = a3ω0(a2I¯ + a1 − b2) sin(kτ0ω0)− a3(b2(a2I¯ + a1) + ω20) cos(kτ0ω0)
+ G¯(−2b1(a3 − a2G¯)(a2G¯+ a3) cos(τ0ω0) + a2b2(a2I¯ + a1)− a2ω20),
v2 = − a3(b2(a2I¯ + a1) + ω20) sin(kτ0ω0)− a3ω0(a2I¯ + a1 − b2) cos(kτ0ω0)
+ 2b1G¯(a
2
2G¯
2 − a23) sin(τ0ω0)− a2G¯ω0(a2I¯ + a1 + b2),
v3 = 2b1G¯(a3 cos((k − 1)τ0ω0) + 2τ0v1 sin(τ0ω0)) + a2(2b1G¯2 cos(τ0ω0) + b2I¯)
+ a1b2 + ω
2
0,
v4 = 2b1G¯(−a3 sin((k − 1)τ0ω0) + a2G¯ sin(τ0ω0)− 2τ0v1 cos(τ0ω0))
+ ω0(a2I¯ + a1 − b2),
v5 = 2(a3b2 sin(kτ0ω0) + ω0(a3 cos(kτ0ω0) + a2G¯)).
Hence, using (5.1.35), (5.1.36), this implies that
C0ω1Z1(a1, a2, a3, b1, b2, k, G¯, I¯, ω0, τ0) = 0,
C0ω1Z2(a1, a2, a3, b1, b2, k, G¯, I¯, ω0, τ0) = 0,
where Z1, Z2 are functions of a1, a2, a3, b1, b2, k, G¯, I¯, ω0, τ0. If C0 = 0, then we obtain
the trivial solution. Additionally, it can be seen that Z1 and Z2 do not vanish modulo
the characteristic curve. Therefore, following our assumption that ω0 does not satisfy
any polynomial equation of lower order, this implies that ω1 = 0. Substituting this,
along with (5.1.30) and (5.1.31), into (5.1.24) and (5.1.25) it can be shown that
u1(s) = a
(1)
1,0 + a
(1)
1,1 cos(s) + b
(1)
1,1 sin(s) + C
2
0h1 cos(2s) + C
2
0h2 sin(2s), (5.1.37)
v1(s) = a
(1)
2,0 + a
(1)
2,1 cos(s) + b
(1)
2,1 sin(s) + C
2
0h3 cos(2s) + C
2
0h4 sin(2s), (5.1.38)
where h1, h2, h3 and h4 are functions of a1, a2, a3, b1, b2, k, G¯, I¯, ω0, τ0. Substituting
(5.1.30), (5.1.31) and (5.1.37), (5.1.38) into (5.1.28), (5.1.29), expressions for α
(2)
1,1,
β
(2)
1,1 , α
(2)
1,2 and β
(2)
1,2 can be obtained. Finally, using conditions (5.1.35), (5.1.36) and
solving the resulting system of equations, it can be shown that the dominant term
for the amplitude, C¯, the second-order term for frequency correction, ω2, and the
period, T , can be expressed as
C¯2 =
W1
V1
2, (5.1.39)
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ω2 =
W2
V2
, T =
2piV2
ω0V2 +W22
, (5.1.40)
where W1, W2, V1 and V2 are functions of a1, a2, a3, b1, b2, G¯, I¯, κ, ω0 and τ0. Given
their length, the expressions are not reproduced here but are used in simulations in
Section 5.2.2.
Derivation of the two conditions (5.1.35) and (5.1.36)
Here we show how conditions (5.1.35), (5.1.36) are obtained. First, we note that
from (3.2.27) and (3.2.28) it can be seen that
cos((k + 1)ω0τ0) =
−b2(a1 + a2I¯)− 2a2b1G¯2 cos(τ0ω0) + ω20
2a3b1G¯
, (5.1.41)
sin((k + 1)ω0τ0) =
ω0(a1 + a2I¯ + b2)− 2a2b1G¯2 sin(τ0ω0)
2a3b1G¯
. (5.1.42)
Through the substitution of the Fourier series decompositions (given by (5.1.33)
and (5.1.34)) into (5.1.24), (5.1.25) and comparing the coefficients of cos(κs) and
sin(κs), we obtain that
a3a
(m)
2,κ cos (κkω0τ0) + a1a
(m)
1,κ + a2G¯a
(m)
2,κ + a2I¯a
(m)
1,κ − a3b(m)2,κ sin (κkω0τ0)
+ κω0b
(m)
1,κ − α(m)1,κ = 0, (5.1.43)
a3a
(m)
2,κ sin (κkω0τ0) + a3b
(m)
2,κ cos (κkω0τ0) + a1b
(m)
1,κ + a2G¯b
(m)
2,κ + a2I¯b
(m)
1,κ
− κω0a(m)1,κ − β(m)1,κ = 0, (5.1.44)
b2a
(m)
2,κ − 2b1G¯a(m)1,κ cos (κω0τ0) + 2b1G¯b(m)1,κ sin (κω0τ0) + κω0b(m)2,κ − α(m)2,κ = 0,
(5.1.45)
b2b
(m)
2,κ − 2b1G¯a(m)1,κ sin (κω0τ0)− κω0a(m)2,κ − 2b1G¯b(m)1,κ cos (κω0τ0)− β(m)2,κ = 0,
(5.1.46)
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which can then be solved for a
(m)
1,κ , a
(m)
2,κ , b
(m)
1,κ and b
(m)
2,κ , with any inhomogeneity, when
κ > 1 (Brandt et al. 2006). The solution of (5.1.43) - (5.1.46) (for κ > 1) is
a
(m)
1,κ =
1
D
{−a1a3b2α(m)2,κ cos(κkτ0ω0) + a1a3b2β(m)2,κ sin(κkτ0ω0)
− 2a2a3b1G¯2α(m)2,κ cos(κ(k − 1)τ0ω0) + 2a2a3b1G¯2β(m)2,κ sin(κ(k − 1)τ0ω0)
+ κω0(a3b2α
(m)
2,κ sin(κkτ0ω0)− 2a3b1G¯α(m)1,κ sin(κ(k + 1)τ0ω0)
+ 2a3b1G¯β
(m)
1,κ cos(κ(k + 1)τ0ω0) + a3β
(m)
2,κ (a2I¯ + a1 + b2) cos(κkτ0ω0)
− 2a2b1G¯2α(m)1,κ sin(κτ0ω0) + 2a2b1G¯2β(m)1,κ cos(κτ0ω0)
+ a2G¯β
(m)
2,κ (a2I¯ + a1 + b2) + a1a3α
(m)
2,κ sin(κkτ0ω0) + κω0(a1α
(m)
1,κ
+ a3α
(m)
2,κ cos(κkτ0ω0)− a3β(m)2,κ sin(κkτ0ω0) + a2G¯α(m)2,κ + a2I¯α(m)1,κ − κω0β(m)1,κ )
+ a2a3I¯α
(m)
2,κ sin(κkτ0ω0)− b22β(m)1,κ ) + b2(a2I¯ + a1)(b2α(m)1,κ − a2G¯α(m)2,κ )
+ 2a3b1G¯ cos(κ(k + 1)τ0ω0)(b2α
(m)
1,κ − a2G¯α(m)2,κ )
+ 2a3b1G¯ sin(κ(k + 1)τ0ω0)(b2β
(m)
1,κ − a2G¯β(m)2,κ )− a2a3b2I¯α(m)2,κ cos(κkτ0ω0)
+ a2a3b2I¯β
(m)
2,κ sin(κkτ0ω0)− 2a22b1G¯3β(m)2,κ sin(κτ0ω0)− 2a23b1G¯β(m)2,κ sin(κτ0ω0)
− 2b1G¯ cos(κτ0ω0)(a23α(m)2,κ + a2G¯(a2G¯α(m)2,κ − b2α(m)1,κ ))
+ 2a2b1b2G¯
2β
(m)
1,κ sin(κτ0ω0)},
b
(m)
1,κ =
1
D
{a1a3b2αm2,κ sin(κkτ0ω0) + a1a3b2βm2,κ cos(κkτ0ω0)
+ 2a2a3b1G¯
2αm2,κ sin(κ(k − 1)τ0ω0) + 2a2a3b1G¯2βm2,κ cos(κ(k − 1)τ0ω0)
− κω0(a3b2βm2,κ sin(κkτ0ω0)− 2a3b1G¯αm1,κ cos(κ(k + 1)τ0ω0)
− 2a3b1G¯βm1,κ sin(κ(k + 1)τ0ω0)− a3αm2,κ(a2I¯ + a1 + b2) cos(κkτ0ω0)
− 2a2b1G¯2αm1,κ cos(κτ0ω0)− 2a2b1G¯2βm1,κ sin(κτ0ω0)− a2G¯αm2,κ(a2I¯ + a1 + b2)
+ a1a3β
m
2,κ sin(κkτ0ω0) + κω0(a1β
m
1,κ + κω0α
m
1,κ + a3α
m
2,κ sin(κkτ0ω0)
+ a3β
m
2,κ cos(κkτ0ω0) + a2G¯β
m
2,κ + a2I¯β
m
1,κ) + a2a3I¯β
m
2,κ sin(κkτ0ω0) + b
2
2α
m
1,κ)
+ 2a3b1G¯ sin(κ(k + 1)τ0ω0)(b2α
m
1,κ − a2G¯αm2,κ) + 2a2b1b2G¯2αm1,κ sin(κτ0ω0)
+ 2a3b1G¯ cos(κ(k + 1)τ0ω0)(a2G¯β
m
2,κ − b2βm1,κ) + a2a3b2I¯αm2,κ sin(κkτ0ω0)
+ a2a3b2I¯β
m
2,κ cos(κkτ0ω0)− 2a22b1G¯3αm2,κ sin(κτ0ω0)
− 2a23b1G¯αm2,κ sin(κτ0ω0) + 2b1G¯ cos(κτ0ω0)(a23βm2,κ + a2G¯(a2G¯βm2,κ − b2βm1,κ))
+ b2(a2I¯ + a1)(a2G¯β
m
2,κ − b2βm1,κ)},
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a
(m)
2,κ =
1
D
{2b1G¯(−a1b2βm1,κ sin(κτ0ω0) + 2a3b1G¯αm1,κ cos(κkτ0ω0)
+ 2a3b1G¯β
m
1,κ sin(κkτ0ω0) + (a2I¯ + a1) cos(κτ0ω0)(a2G¯α
m
2,κ + b2α
m
1,κ)
− a2b2I¯βm1,κ sin(κτ0ω0) + a3(a2I¯ + a1)αm2,κ cos(κ(k + 1)τ0ω0)
+ a3(a2I¯ + a1)β
m
2,κ sin(κ(k + 1)τ0ω0) + a1a2G¯β
m
2,κ sin(κτ0ω0)
+ a22G¯I¯β
m
2,κ sin(κτ0ω0))− κω0(2b1G¯(sin(κτ0ω0)(αm1,κ(a2I¯ + a1 + b2)
+ a2G¯α
m
2,κ) + cos(κτ0ω0)(β
m
1,κ(a2I¯ + a1 + b2)− a2G¯βm2,κ)
+ a3α
m
2,κ sin(κ(k + 1)τ0ω0)− a3βm2,κ cos(κ(k + 1)τ0ω0)) + (a2I¯ + a1)2βm2,κ
+ κω0(−b2αm2,κ + κω0βm2,κ + 2b1G¯αm1,κ cos(κτ0ω0)− 2b1G¯βm1,κ sin(κτ0ω0)))
+ 4a2b
2
1G¯
3αm1,κ + b2(a2I¯ + a1)
2αm2,κ},
b
(m)
2,κ =
1
D
{2b1G¯(a1b2αm1,κ sin(κτ0ω0)− 2a3b1G¯αm1,κ sin(κkτ0ω0)
+ (a2I¯ + a1) cos(κτ0ω0)(a2G¯β
m
2,κ + b2β
m
1,κ) + a2b2I¯α
m
1,κ sin(κτ0ω0)
− a3(a2I¯ + a1)αm2,κ sin(κ(k + 1)τ0ω0) + a3(a2I¯ + a1)βm2,κ cos(κ(k + 1)τ0ω0)
− a1a2G¯αm2,κ sin(κτ0ω0)− a22G¯I¯αm2,κ sin(κτ0ω0) + 2a3b1G¯βm1,κ cos(κkτ0ω0))
+ κω0(−2b1G¯(− cos(κτ0ω0)(αm1,κ(a2I¯ + a1 + b2)− a2G¯αm2,κ)
+ sin(κτ0ω0)(β
m
1,κ(a2I¯ + a1 + b2) + a2G¯β
m
2,κ) + a3α
m
2,κ cos(κ(k + 1)τ0ω0)
+ a3β
m
2,κ sin(κ(k + 1)τ0ω0)) + (a2I¯ + a1)
2αm2,κ + κω0(κω0α
m
2,κ + b2β
m
2,κ
− 2b1G¯(αm1,κ sin(κτ0ω0) + βm1,κ cos(κτ0ω0)))) + 4a2b21G¯3βm1,κ
+ b2(a2I¯ + a1)
2βm2,κ}, (5.1.47)
where
D =κω0(−4b1G¯(a2I¯ + a1 + b2)(a3 sin(κ(k + 1)τ0ω0) + a2G¯ sin(κτ0ω0))
+ κω0(−4b1G¯(a3 cos(κ(k + 1)τ0ω0) + a2G¯ cos(κτ0ω0)) + (a2I¯ + a1)2 + b22)
+ κ3ω30) + 4b1G¯(a2G¯(2a3b1G¯ cos(κkτ0ω0) + b2(a2I¯ + a1) cos(κτ0ω0))
+ a3b2(a2I¯ + a1) cos(κ(k + 1)τ0ω0)) + 4b
2
1G¯
2(a22G¯
2 + a23) + b
2
2(a2I¯ + a1)
2.
Note that when κ = 1, D = 0, and therefore we must re-examine (5.1.43) - (5.1.46)
for κ = 1. By taking (ω0 (5.1.43) + (a2G¯ + a3 cos kτ0ω0) (5.1.46)) − (b2 (5.1.44)
− (a3 sin kτ0ω0) (5.1.45)) we obtain (5.1.35). Similarly, by taking (b2 (5.1.43) −
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(a2G¯ + a3 cos kτ0ω0) (5.1.45)) + (ω0 (5.1.44) + (a3 sin kτ0ω0) (5.1.46)) we obtain
(5.1.36).
5.2 Parameter analysis
The closed form expressions for the limit cycles presented in Sections 5.1.1 and 5.1.2
allow for the effect of changes in each of the model parameters on the amplitude
and period to be more easily studied. This section is split into two parts. Firstly,
the effect of changes in a2 (insulin resistance), b1 (insulin secretion) and b2 (insulin
degradation) on the important characteristics of the waveforms for the constant
hepatic production model solutions are explored. Secondly, we investigate how the
amplitude and period of model (5.1.20) vary with respect to the commensurate delay
parameter k.
5.2.1 Constant hepatic glucose production
In this section, the closed form expressions for the amplitude and period of model
(5.1.1), as given by (5.1.17), (5.1.18) and (5.1.19), will be analysed using two different
Parameter Sets, which are given in Table 5.1. The values used in Parameter Set
1 are based off the values used in Sturis et al. (1991), Li et al. (2006), and Huard
et al. (2015), and represent a patient under a constant glucose infusion. Parameter
Set 2 looks to replicate the values that may be observed in a patient under a larger
constant glucose infusion.
On the quantification of insulin sensitivity
To begin, we analysed the relationship between the insulin sensitivity parameter,
a2, and the closed form expressions for the amplitude and period of model (5.1.1).
It can be seen from Fig. 5.1 that the amplitude of X(t), as given by (5.1.17), varies
between 4 and 15 for Parameter Set 1, and 1 and 38 mg/dl for Parameter Set 2.
Additionally, the amplitude of Y (t) from (5.1.18) is observed to be approximately
between either 1 and 5, or 1 and 29 mU/l. These values are within a physiologically
acceptable range. Furthermore, in Figure 5.2 we note that the values of the period,
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Parameter Set 1 Parameter Set 2 Units
a0 1300 1800 mg min
−1
a1 2.02982× 10−4 2.02982× 10−4 min−1
b1 6.01344× 10−8 9.01344× 10−8 mU mg−2 min−1
b2 0.06 0.064 min
−1
τ 20 20 min
Table 5.1: Parameter Sets 1 and 2 which are used in numerical simulations through-
out Section 5.2.1.
as defined by (5.1.19), vary between 74.5 and 76 minutes for Parameter Set 1, and
76 and 78 minutes for Parameter Set 2, and hence are also within an acceptable
range.
Figure 5.1: Amplitudes of the oscillations, A¯ and B¯, as a function of a2 using
Parameter Set 1 (left) and Parameter Set 2 (right).
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Figure 5.2: Period of the oscillations, as given by (5.1.19), as a function of a2 using
Parameter Set 1 (left) and Parameter Set 2 (right).
It can be seen in Fig. 5.3 that increasing a2 has little consequence on the oscil-
lations, while decreasing a2 has a more profound effect. For example, for Parameter
Set 1 a 20% increase in a2 from 0.0017 increases the amplitude by 15%. However, a
20% decrease in a2 reduces the amplitude by almost 80%. Similarly for Parameter
Set 2, a 20% increase in a2 from 0.0004 increases the amplitude by less than 5%
while a 20% decrease in a2 reduces the amplitude by approximately 30%. It is noted
that a2 has a much deeper influence on the amplitude of the oscillations compared
to the period.
Figure 5.3: Percentage change of the closed form expressions of the amplitude (blue)
and period (black) of Y (t), which are given by (5.1.18) and (5.1.19) respectively, vs.
the percentage change in a2 for Parameter Set 1 (left) and Parameter Set 2 (right).
The initial value used for a2 was: 0.0017 (left); and 0.0004 (right).
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Insulin secretion capacity b1 and insulin degradation b2 vs. amplitude of
X(t) and Y (t)
Next, we look at the relationship between the insulin secretion capacity, b1, and
the closed form expression of the amplitude of X(t) defined by (5.1.17). As shown
in Fig. 5.4, the amplitude variation with respect to b1 is between 0 and 19 for
Parameter Set 1, regardless of the value of a2 used. However, a2 does have an effect
on the decline of amplitude observed with an increased b1. Indeed, as a2 increases,
the observed value of b1 such that the amplitude begins to decrease, decreases. This
effect is also observed with Parameter Set 2.
Fig. 5.5 shows the effect of b2 on the amplitude of X(t) and Y (t), respectively,
for Parameter Set 1. It is observed from both that the oscillations are lost when
b2 drops below ≈ 0.059 regardless of the value of a2. Indeed when looking at the
amplitude as a function of b2, a2 has very little effect of A¯ and only a small effect on
B¯ for Parameter Set 1. However, as seen in Fig. 5.6, this is not true for Parameter
Set 2, where a2 has a more profound effect on both the amplitude of X(t) and Y (t).
Irrespective of this, it is observed for both Parameter Sets that an increase in b2
leads to an increase in the amplitude of the oscillations. This was also observed by
Li et al. (2006, Fig. 12). While the size of the oscillations of Y (t) in Fig. 5.5 and
Fig. 5.6 are plausible for all values of b2, the size of the oscillations of X(t) become
too large with b2. Indeed, eventually the value of G¯ − A¯ drops below 70 mg/dl
in both cases. Physiologically, this would mean the onset of hypoglycaemia. The
ranges 0.06 < b2 < 0.062 for Parameter Set 1, and 0.064 < b2 < 0.075 for Parameter
Set 2 ensure that glucose levels are kept within a realistic physiological range.
5.2.2 Non-constant hepatic glucose production
We now move on to investigate the effect of the two delays on the closed form
expressions for the amplitude and period of model (5.1.20). In particular, we focus
on the relationship between the amplitudes of X(t) and Y (t), given by (5.1.39) and
(5.1.32) respectively, and the commensurate delay parameter k. Using Parameter
Set 1 with a2 = 0.0017, it can be seen in Fig. 5.7 that when a3 is small, k has
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Figure 5.4: Amplitude of X(t), as given by (5.1.17), vs. b1 for Parameter Set 1 (left)
and Parameter Set 2 (right).
Figure 5.5: Amplitude of X(t) (left) and Y (t) (right), as given by (5.1.17) and
(5.1.18) respectively, vs. b2 for Parameter Set 1.
a negligible effect on the amplitude. Additionally, when a3 < O(10
−2) changes in
a3 also have a negligible effect on the amplitudes. However, when a3 = 0.1 it is
observed that the amplitude of both X(t) and Y (t) vary with k in an oscillatory
manner.
To further investigate how the closed form expressions for the amplitude and period
vary with k, we now look into the variation using the parameter values given in
Table. 5.2. From Fig. 5.8 we can see that k has a large influence on both the
amplitude and period for Parameter Set 3. Indeed, increasing k from 1 to 7 leads
to the amplitude increasing by ≈ 700% and the period by ≈ 500%. However, it
must be noted that for k > 1 the values of the amplitude and period are not in a
physiological range. This is most likely due to the size of 2. Indeed, when k = 7
we note that 2 = 9.49476 compared with 0.2806 when k = 1. Therefore, instead
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Figure 5.6: Amplitude of X(t) (left) and Y (t) (right), as given by (5.1.17) and
(5.1.18) respectively, vs. b2 for Parameter Set 2.
Value Units
a0 285 mg min
−1
a1 2.02982× 10−4 min−1
a2 0.00009 mU
−1 min−1
a3 1.415 mg mU
−1 min−1
b1 9.3× 10−8 mU mg−2 min−1
b2 0.06 min
−1
τ 16 min
Table 5.2: Parameter Set 3.
of setting τ = 16 we shall instead we shall instead fix 2 = 0.16 and compute the
resulting value of τ = τ0 + 
2, thus ensuring the perturbed solution remains close
to the threshold curve. The results can be seen in Fig. 5.9. Here we observe that
the amplitude remains in a physiological range for 1 ≤ k ≤ 7, and that the period
of the oscillations is within an acceptable physiological range for insulin levels. We
also note that there is very little variation in the amplitude when k increases. This
implies more accurate values of the two delays can be chosen without losing the
physiological accuracy of the oscillations.
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Figure 5.7: Amplitude of X(t) (left) and Y (t) (right), as defined by (5.1.39) and
(5.1.32) respectively, as a function of k for Parameter Set 1 with a2 = 0.0017.
Figure 5.8: Amplitude of X(t) (left) and Y (t) (right), as defined by (5.1.39) and
(5.1.32) respectively, vs. k for Parameter Set 3.
Figure 5.9: Amplitude of X(t) (left) and Y (t) (right), as given by (5.1.39) and
(5.1.32) respectively, vs. k for fixed . All other parameters are as defined in Table
(5.2).
Chapter 6
Discussion and Conclusions
The theoretical and numerical results obtained in Sections 3.1.2, 4.2 and Chapter 5
have highlighted the effect of diabetic deficiencies on the cyclic regulation of glucose
and insulin in the ultradian regime. The regulatory negative feedback loop, which is
modelled by taking into account production times for pancreatic insulin and hepatic
glucose, provides an important mechanism for investigating this regulation. On one
hand, model (3.1.1) predicts a dampening of the oscillations in the case of a reduced
capacity to utilise insulin to degrade glucose. This behaviour was observed in clini-
cal trials involving constant glucose infusions in type-2 diabetic patients (O’Meara
et al. 1993). Note that a similar effect of insulin resistance was also noted on the
production of fast oscillations (Lang et al. 1981) (see also e.g. Nepton (2013) for a
general review of the effect of diabetes on β-cell activity). On the other hand, the
usage of model (3.1.1) has permitted the recovery of healthy regulation through the
original objectives: (i) the production an oscillatory regime while (ii) stabilising the
average glucose levels within a physiologically acceptable range.
Here we highlighted the importance of considering variable insulin degradation
rates as these have an important effect on the production of an oscillatory regime.
By considering the insulin clearance term as a combination of both natural and ex-
ternal mechanisms for the degradation of insulin and combining its effect with other
parameters such as insulin sensitivity, pancreatic secretion and hepatic glucose pro-
duction, four strategies have been investigated in Section 4.2. We have shown that
it is generally possible to individually alter these parameters, either positively or
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negatively, to stabilise average glucose levels. These alterations take into account
current therapeutical pathways, such as insulin infusions and drugs that inhibit hep-
atic glucose production such as Metformin, which typically only focus on reducing
glucose levels. The effect of this manipulation on the generation of oscillations has
been investigated. We then established regions in the space of diabetic parame-
ters α and β where both objectives can be achieved. In several cases, it would be
worth considering combinations of these strategies in order to deliver an optimal
treatment which combines the benefits of having an oscillatory regime within an
acceptable range. Splitting the insulin contribution into dynamically linked com-
partments accounting for plasma and remote insulin with individual transfer and
degradation rates, as done by Wu et al. (2011), may as well lead to more precise
recovery pathways. Such a study is currently under way.
However, at this stage, the qualitative contribution of the strategies described
in Section 4.2 should be considered more important than specific numerical values.
One reason for this is that insufficient exhaustive characterisations of the ultradian
oscillatory regulation of diabetically-impaired systems are available. Additionally, it
is known physiologically that both T1DM and T2DM are linked to many changes in
the body, and not just variation in insulin secretion and insulin sensitivity, respec-
tively. For example, in patients with T2DM it is observed that insulin resistance,
insulin secretion and insulin degradation are altered at various stages of the disease
(Kotronen et al. 2008, Pories & Dohm 2012). Hence, from a physiological point of
view, the model parameters may depend on time and/or other model parameters,
e.g. β = β(t) and/or τ1 = τ1(G(t)), i.e. the delay in pancreatic insulin secretion
may be state dependent. Nevertheless, the model appears to be sufficiently robust
for qualitatively establishing the effect of diabetic parameters. For instance, adding
a 5% white noise to the diabetic parameters does not incur very large variations
in the period and amplitude of the oscillatory regime, as shown in Fig. 6.1. Two
approaches could be employed in order to strengthen the current proposed pathways
and provide a more quantitative framework. Firstly, appropriately designed clinical
trials aiming at evaluating variations in oscillatory patterns in subjects at various
diabetic states under glucose infusions would be of great value. Secondly, new mul-
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Figure 6.1: Ultradian oscillations with a 5% noise on α and β around α = β = 1.
The middle band represents the associated variability of G¯. A similar effect can be
observed on insulin patterns. Simulation performed with 500 repetitions.
tiscale simulations taking into account dynamics at the β-cell secretion level, as
performed by De Gaetano et al. (2015) in the case of decreased insulin sensitivity,
could lead to a further assessment of the current model against clinical observations.
Indeed, model (3.1.1) could be adapted to incorporate these dynamics at the β-cell
secretion level through the introduction of state-dependent delays, especially thresh-
old delays. Such a model would allow for the maturation and release dynamics of
insulin within the pancreas to be taken into account. The characterisation of peri-
odic solutions in these systems is generally challenging, though theoretical results in
this direction have been obtained by Smith & Kuang (1992), as well as by Gourley,
Liu & Lou (2017) where a new approach was used to investigate the presence of
periodic rhythms in insect larvae development.
In Chapter 5, a simplified polynomial version of model (3.1.1) is explored using
a nonlinear analysis to investigate the effect of various diabetic parameters on the
ultradian oscillations. The model is split into two sub-models, one with a constant
hepatic glucose production (5.1.1) and one with a linear hepatic production con-
taining a commensurate delay (5.1.20). Indeed, by performing a P-L perturbation
method we have been able to obtain analytical expressions that are based on the
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model parameters for the linearised amplitude and period of the two sub-models.
From a Mathematical point of view, the accuracy of these expressions is of a high
degree. Indeed, from Fig. 6.2 we can see that the closed form expression for the
amplitude of X(t) given by (5.1.17) is almost an exact match for the amplitude
obtained through numerical simulations. Furthermore, Fig. 6.3 shows that the solu-
tions for G(t) and I(t) of model (5.1.1) obtained using the P-L technique are a good
approximation to the solutions calculated using a classical Runge-Kutta method.
From a physiological perspective, it is important to note while the values of the
amplitude of X(t) in Figure 5.1 are within a physiologically acceptable range, the
decrease in amplitude in the presence of mild insulin resistance is most notably seen
experimentally in insulin levels, while the amplitude of the glucose oscillations has
been observed to remain almost constant (O’Meara et al. 1993). Therefore, the
expressions derived in Chapter 5 could theoretically be used to obtain estimates for
insulin sensitivity through the matching of clinical insulin data to models (5.1.1) and
(5.1.20). Additionally, we note that strategies aiming to restore glucose-insulin os-
cillations could make use of the fact the amplitude and frequency of the oscillations
show very little variation in the vicinity of the Hopf threshold curve in the space
of delays. These theoretical findings could therefore have an impact on optimal
glycemic control.
Moreover, we have shown that taking into account an instantaneous glucose-
dependent insulin production, through the introduction of an additional coefficient,
enables us to characterise the existence of sinusoidal solutions by investigating roots
of a cubic polynomial. This provides an additional means for investigating the curve
of Hopf bifurcations, which separates asymptotically stable and oscillatory regimes
in system (3.1.1), without relying on a transcendental equation. It is numerically
evidenced to be part of a closed loop in the (τ1, τ2) domain.
Finally, in view of the recent efforts for the development of an artificial pancreas,
the results in this thesis open the way for more in-depth analysis of the underlying
mechanisms which are most responsible for generating the oscillations. The presence
of periodic solutions in the (τ1, τ2) domain can be detected using Proposition 5 and
these could be used for further investigation of the mechanisms involved in the
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Figure 6.2: Comparison of two methods for calculating the amplitude of X(t) from
model (5.1.1) using Parameter Set 1. The blue line represents the P-L approxima-
tion given by (5.1.17) and the black dots represent the numerical approximations
obtained using a Runge - Kutta method.
oscillatory regulation. In particular, combining strategies discussed in Section 4.2
may provide additional pathways for reintroducing a physiologically appropriate
cyclic regulation and devise new regimes for personalised treatment.
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Figure 6.3: Comparison of the limit cycles corresponding to the P-L approximation,
given by (5.1.17), (5.1.18) and (5.1.19), and the numerical solution of system (5.1.1).
Parameter values are as defined in Parameter Set 1, with a2 = 0.002.
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